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Alzheimer‟s disease (AD) is the most prevalent neurodegenerative disorder in the US, 
affecting over 1 in 8 people over the age of 65.  There are several well-known 
pathological changes in the brains of AD patients, namely: the presence of diffuse 
beta amyloid plaques derived from the amyloid precursor protein (APP), hyper-
phosphorylated tau protein, neuroinflammation and mitochondrial dysfunction.  
Recent studies have shown that cholesterol levels in both the plasma and the brain 
may play a role in disease pathogenesis, however, this exact role is not well 
understood.  Additional proteins of interest have also been identified (ApoE, LRP-1, 
IL-1) as possible contributors to AD pathogenesis.  To help understand these roles 
better, a systems biology mathematical model was developed.  Basic principles from 
graph theory and control analysis were used to study the effect of altered cholesterol, 
ApoE, LRP and APP on the system as a whole.  Negative feedback regulation and the 
  
rate of cholesterol transfer between astrocytes and neurons were identified as key 
modulators in the level of beta amyloid.  Experiments were run concurrently to test 
whether decreasing plasma and brain cholesterol levels with simvastatin altered the 
expression levels of beta amyloid, ApoE, and LRP-1, to ascertain the edge directions 
in the network model and to better understand whether statin treatment served as a 
viable treatment option for AD patients.  The work completed herein represents the 
first attempt to create a systems-level mathematical model to study AD that looks at 
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Chapter 1: Introduction 
 
Alzheimer‟s disease (AD) is the most common form of dementia, affecting 
more than 4.5 million individuals in the US alone [65].  This number is expected to 
triple in the next four decades as the most affected age group (those over 65) 
surpasses 12 million.  The cost of care for individuals with AD is staggering- over 
$140 billion annually, which is also expected to rise in correlation with the affected 
number of individuals.  The exact cause of AD is uncertain, though at least two 
distinct forms of the disease are known to exist: early-onset and late-onset.  
 Early-onset AD is related to mutations in the amyloid precursor protein (APP) 
and presenilin, which increase the cleavage rate of APP into the amyloidogenic beta 
amyloid (Aβ).  Individuals with Down Syndrome (DS; also known as trisomy 21) 
also commonly have early-onset AD because the gene for APP is located on 
chromosome 21.  Late-onset AD has been linked to age, the presence of the 
apolipoprotein ε4 allele, cerebrovascular disease, cardiovascular disease (including 
atherosclerosis) and high plasma cholesterol, though the exact interactions between 
these co-occurring diseases are not well understood.   
 Regardless of the disease trigger(s), the resultant pathological characteristics 
are similar and involve the buildup of Aβ in the brain parenchyma, deposition of Aβ 
in the cerebral blood vessels (as cerebral amyloid angiopathy, CAA), as well as the 
presence of neurofibrillary tangles (NFTs).  Loss of hippocampal and cortical neurons 




microglia has also been observed, as well as alterations in blood-brain barrier (BBB) 
permeability [121, 156-159, 6-67].  A combination of these cellular and sub-cellular 
changes is believed to lead to the symptoms most commonly associated with AD, 
including: gradual loss of memory, personality changes, depression, inability to 
communicate, and loss of voluntary muscle movements [94].   
 Even with the significant advances that have been made in the field of AD 
research, there is still no clear understanding between causality and observation of 
secondary symptoms.  Specifically, no systems-level, biomolecular reaction network 
exists to describe how different biomolecules that are known or thought to be 
involved in the pathogenesis are interrelated.  The goals of this dissertation were: 
1) To develop an interaction network model of the biomolecular processes 
involved in AD pathogenesis using systems biology and graph theory as the 
basis for analysis. 
2) To study the role of brain cholesterol and inflammation in the disease process 
via: 
a. Experimental methods that simultaneously decrease the level of brain 
cholesterol and neuroinflammation, and provide semi-quantitative data 
points for the effect of a network perturbed by such a decrease. 
b. Computational methods that utilize experimental data to describe 
connections and connection strengths between components in the 




This dissertation represents the first (known) attempt to create a systems biology 
model to better understand the processes that are co-occurring in AD and how these 




Chapter 2: Background 
 
 
History of neuroscience 
The human mind has been the center of much study and discussion since 
ancient times.  The earliest surviving manuscript referencing the brain and brain 
surgery is a collection of papyrus documents from Egypt dating back to 3000 BC.  It 
is not until nearly 2500 years later that Hippocrates describes the importance of the 
brain in intelligence and in feeling sensations.  This view is debated among several 
other prominent philosophers of the era, including Aristotle who believed that the 
heart was the source of sensations and mental processes.  Herophilus and his student, 
Erasistratus, conducted anatomical studies of the brain and believed that the ventricles 
were the source of human intellect and the soul.  Galen (129-199 AD) was the first to 
describe the brain, spinal cord and nerves as one system, the nervous system, and to 
conclude that the soul does not reside in the ventricles of the brain through 
experimental observation.   
Further understanding of the brain and nervous system paused during the 
Middle Ages, and resumed during the Renaissance and thereafter, with contributions 
by several major physicians and philosophers.  In 1543, Andreas Vesalius argued that 
brain function derives from the tissue surrounding the ventricles (the cortex and other 
regions of the brain), and not the ventricles.  The term “hippocampus” was introduced 




appear in 1609 when Guilio Casserio published drawings of the circle of Willis (a 
circle of arteries located at the base of the brain).  This work was expanded on by 
Thomas Willis in 1664 who published a work discussing the function of the arteries at 
the base of the brain that now carry his name.   
The 18
th
 century brought significant advances in the anatomical knowledge of 
the central nervous system, including description of the composition of cerebrospinal 
fluid, and identification of foramen of Monroe, the stripe of Gennari, the fovea and 
the insula.   It was also the first time that electrical impulses in nerves were studied in 
an animal model.  The first hospitals dedicated to helping those affected by mental 
illness also opened during the 18
th
 century.   
Neuroscience flourished in the 19
th
 century.  Basic anatomy and physiological 
functions of identified regions were described.  In 1837, Jan Purkyne (Purkinje) 
successfully identified neuronal nuclei and associated processes in cerebellar cells. 
Robert Remak described the difference between myelineated and unmyelineated cells 
in 1836; Schwann cells were soon after discovered by Theodor Schwann in 1838.  In 
1850, Augustus Waller first described degenerating neurons.  Richard Caton was the 
first person to record electrical activity from the brain in 1875, beginning the era of 
using electrical recordings to study brain functionality.  Many of the stains and 
methods that we still use today in histology were developed in the last 30 years of the 
19
th
 century (silver nitrate, 1873; hematoxylin to stain myelin, 1885; Nissl stain for 
neurons, 1894; formaldehyde to fix brains, 1897).  This was also the time period 
wherein Golgi and Ramon y Cajal did their groundbreaking histological work and 






 century continued this trend of rapid expansion of knowledge.  A 
single paragraph cannot do justice to the vast amount of information gained in the last 
111 years, but only touch on some of the key points.  Early in the century, glial cells 
(astrocytes, microglia and oligodendrocytes) were identified and their roles were 
characterized.  Cellular ultrastructure of all neural cell types was obtained in the 
1950s with the advent of the electron microscope, providing definitive proof of the 
validity of Ramon y Cajal‟s cellular theory for the brain.  This led to the development 
of neural circuit models to study physiological functioning and development in the 
brain.  Neurotransmitters were identified as the key electrochemical signaling 
molecule within the brain, leading to the concept of excitatory and inhibitory 
neurotransmitters, a key factor playing a role in a variety of neurological and 
psychiatric diseases.  It was also in this century that Alois Alzheimer first described 
the symptomology and amyloid beta plaques present in a patient with presenile 
degeneration, a disease that would later take on his name. 
Although our understanding of the brain, its anatomy, physiology and 
development has grown almost exponentially in the last 200 years, there are still 
many unknowns.  Of all of the subfields in biology and medicine, neuroscience is 
perhaps the last, towering frontier to understand and conquer.  With the advent of 
modern computing capabilities; technological advances in imaging, metabolomics, 
genomics and proteomics; and development of a mathematical language to help 
describe the interaction of a large number of biological networks, neuroscientists 





Anatomy of the brain 
 In humans, that brain starts to form during the first 3 weeks of gestation, with 
the ectoderm forming the neural plate, followed by the neural plate folding and 
closing to form the neural tube.  As development continues, the neural tube starts to 
take shape into the cerebral hemispheres, cerebellum and pons.  Continuing 
development of the brain proceeds throughout the early years following birth all the 
way into young adulthood, wherewith neurons are shed, neurons grow slowly, and 
near-constant pruning of dendrites and wiring/re-wiring occurs.  Development of the 
brain continues until the early- to mid-twenties, when rates begin to converge.  
Generation of neurons in the dentate gyrus has been shown to continue well into 
adulthood, however, the rates are quite slow comparatively.   
Together, the brain with the spinal cord, are known as the central nervous 
system (CNS).  The CNS can be divided into six majors divisions: spinal cord, 
medulla, pons and cerebellum, midbrain, diencephalon and cerebral hemispheres.  
Each of these regions performs a set of tasks; however, these tasks are not necessarily 
independent or unique from tasks performed by other CNS regions.  Each region can 
also be clearly subdivided into regions containing neuronal cell bodies (gray matter) 
and regions containing predominantly axons (white matter).  White matter is white 
due to the high concentration of myelin which surrounds the axons.  The CNS is 
surrounded by three layers of meninges which serve a protective, as well as 
circulatory role.    These three meninges are known as the dura mater, the arachnoid 
mater and the pia mater.  The dura mater contains large, low-pressure blood vessels 




from the pia, creating the subdural space and the subarachnoid space, respectively.    
The subarachnoid space contains the veins and arteries that provide circulation to the 
surface of the CNS, as well as cerebrospinal fluid (CSF).  The following sections will 
describe in further detail the brief functions of each brain region aside from the spinal 
cord. 
The brain stem is composed of the medulla, pons, midbrain and cerebellum 
and has three main functions: (1) to receive sensory information from cranial nerves 
and control muscles of the head; (2) to regulate the level of arousal via blood pressure 
regulation and respiratory regulation by the combined effort of the medulla, pons and 
midbrain; and (3) to act as a multiplexor of information between the spinal cord and 
higher brain regions.  The cerebellum also plays a key role in the control of muscle 
movement, while the midbrain plays an important role in the control of eye 
movement. 
 The most developed regions of the human brain are the diencephalon and the 
cerebral hemispheres.  The diencephalon is subdivided into the thalamus and the 
hypothalamus.  The thalamus is responsible for transmitting information between the 
two cerebral hemispheres.  The hypothalamus is responsible for regulating release of 
hormones from the pituitary gland, as well as integrating the functions of the 
autonomic nervous system.  The sagittal fissure separates the two hemispheres of the 
cerebrum.  The cerebrum can be further divided into the cerebral cortex, basal 
ganglia, amygdala and hippocampus.  The basal ganglia, also known as the striatum, 
contribute to several higher brain functions, including control of movement, cognition 




neurons found on the surface of the cerebrum, is responsible for the many of the 
functions attributed to the brain.  The cerebral cortex can be divided into four distinct 




The frontal lobe is responsible for many of the higher mental functions of the 
brain, including suppressing unacceptable social responses, choosing between wrong 
and right, recognizing consequences and differentiating between objects, events or 
people.  The frontal lobe contains the majority of the neurons that are sensitive to 
dopamine; dopamine-sensitive neurons are responsible for actions associated with 
planning, drive, long-term memory, reward and attention.  The long-term memories 
stored in the frontal lobe are often associated with emotion-based memories inputted 
Figure 1: Sagittal view of right brain hemisphere.  Details of the brain stem (pons, 




from the limbic system.  Lesions in the frontal lobe can be associated with loss of 
creativity and decreased ability to have higher mental processes. 
The parietal lobe is responsible for visual-spatial processing, understanding 
mathematics and abstract, symbolic representations, as well as integrating sensory 
input from different regions of the body.  The temporal lobe plays important roles in 
processing visual and auditory signals.  It contains the auditory cortex.  The occipital 





The final two regions of the cerebral cortex are the amygdala and the 
hippocampus.  The amygdala is believed to be responsible for hormone release, 
coordination of the autonomic nervous system, and emotional responses.  The 
Figure 2: The four lobes of the cerebral cortex. Frontal: “moral differentiator”, emotion-
based memories; Parietal: Visuo-spatial processing, symbolic representation, integrating 
sensory input; Temporal: Auditory and visual processing, auditory cortex; Occipital: 




hippocampus, the brain region that is initially and most severely affected in AD, is 
believed to play a role in episodic memory and spatial orientation.  The hippocampus 
can be further subdivided into 4 distinct regions: CA1, CA2, CA3 and DG (Cornu 
Ammonis and dentate gyrus, respectively).  Modulatory inputs are received from the 
dopamine, serotonin, and norepinephrine systems; from the nucleus reuniens of the 
thalamus via CA1; and cholinergic and GABAergic input from the medial septal area.  
Together, the hippocampus, amygdala, and portions of the midbrain and diencephalon 
form the limbic system, which is believed to be responsible for thought and mood in 




Supplying each of these regions of the brain with nutrients and removing 
waste products is a complicated network of arteries, capillaries and veins.  On 
Figure 3: The hippocampus and surrounding regions. The hippocampus is believed to 





average, neurons are less than 50 μm away from an artery, ensuring that they receive 
an adequate supply of glucose and oxygen for metabolism, and removal of neurotoxic 
waste products.  These vessels are not immune from the buildup of plaques, leading 
to strokes, poor microcirculation or localized hypoxia, and eventual neuronal cell 
death.  In AD, beta amyloid plaques are found in cerebral blood vessels, which may 
play a causal role in disease pathogenesis. 
Cellular Neurobiology: 
 At the cellular level, the brain can be divided up into two main types of cells: 
neurons and glial cells.  The average brain contains over 100 billion neurons and 
more than four times that many glial cells.  Neurons are specialized cells that have 
been terminally differentiated.  Their predominant role is to receive incoming 
electrical signals from neighboring neurons, process the signal, and transmit the 
corresponding output signal to downstream neurons via the axon and synapse.  Glial 
cells participate in a range of supporting activities, from removing wastes and excess 
neurotransmitters from the synaptic cleft, to providing dendrites some guidance on 
where to grow and acting as the brain‟s immune system. 
 There is a rich diversity in the types of neurons in the brain.  Neurons vary in 
shape, size and length of axon (morphology), expression of receptors and proteins 
(proteomic variation), and in physiological function.  The basic components of any 
neuron are: a cell body, the axon, and the dendrites.  The dendrites are the location 
where axons from other neurons synapse onto a neuron, and signals are transmitted to 
the cell body for further processing.  The cell body is the predominant site of protein 




by the cell body and are transmitted down the axon in generally a unidirectional 
manner (there are a few exceptions to this).  The axon is encased in a layer of myelin, 
which insulates the axon and allows electrical signals to travel faster.  In mammals, 
the myelin covers distinct areas of the axon while leaving occasional areas un-
insulated.  These un-insulated areas are known as the nodes of Ranvier and give the 
action potential an appearance of “jumping” from node to node, an observance that 
has been named saltatory conduction. Together, this basic structural unit is capable of 




Figure 4: A sampling of some of the types of neurons that are found in the brain.  
Notice how many different variations on the standard textbook neuron (cell body, axon, 
dendrites) there are, and how the dendritic structure can vary greatly.  Adapted from 
Neuroscience by Purves 2
nd




 At the axon terminal and dendrites, specialized proteins aggregate and help 
form what is known as the synapse.  The synapse is composed of two terminals (pre- 
and post-) and extracellular space in between the two known as the synaptic cleft.  As 
an action potential reaches the axon terminal, membrane depolarization causes 
membrane-gated Ca
2+
 to open, triggering the influx of calcium into the pre-synaptic 
terminal.  The increased calcium levels cause synaptic vesicles to move to the pre-
synaptic membrane and release neurotransmitter into the synaptic cleft.  
Neurotransmitter is then bound by receptors at the post-synaptic site, triggering an 
action potential in the post-synaptic cell.  Neurotransmitters can be excitatory, 
inhibitory or some combination thereof; that is, they can either increase the 
probability of an action potential (excitatory) or decrease the probability (inhibitory).  
Used neurotransmitter is released back into the synaptic cleft and either recycled by 
the pre-synaptic cell or degraded via enzymatic action.  The following table lists some 
of the most common neurotransmitters in the brain, their function and which type of 
neurotransmitter they are. 
Neurotransmitter Type Function 
Acetylcholine ---- Excitatory 
Dopamine Amine Excitatory & Inhibitory 
Epinephrine Amine Excitatory 
Nor-epinephrine Amine Excitatory 
Serotonin Amine Excitatory 
Glutamate Amino Acid Excitatory 
Glycine Amino Acid Mainly inhibitory 
GABA Amino Acid Inhibitory 
  
Table 1: Common neurotransmitters in the brain.  Neurotransmitters belong to one of 
three main groups: amine, amino acid or acetylcholine.  Within this distribution, 




 Glial cells, derived from the Greek word glia meaning glue, are also a very 
diverse cell type, ranging from Müller cells found in the retina, to astrocytes located 
in regions throughout the brain.  Some cell types are isolated to specific regions of the 
brain and perform specialized functions, while others are more broadly distributed 
and perform a wide variety of tasks.  Of all glial cells, there are only three main types: 
astrocytes, oligodendrocytes and microglia.  Astrocytes are star-shaped cells that are 
found in nearly all brain regions.  Oligodendrocytes are the oblong, heavily myelin-
producing cells that are found surrounding axons in the CNS.  Microglia are 
macrophage cells that function as the brain‟s immune cells.  Astrocytes and 
oligodendrocytes originate from neural stem cells, whereas microglia originate from 
the immune system. 
Glial Cell Type Main Function Sketch 
Astrocytes Biochemical support 
 
Microglia Immune system in brain 
 
Oligodendrocytes 
Provide myelin sheath for 




Table 2: The major types of glia.  Astrocytes, oligodendrocytes and microglia are the three 
main types of glial cells found in the CNS.  Each serves unique and important roles, helping to 




 Glial cells were initially believed to play only supportive roles in the CNS, 
particularly for structural support.  Research over the last 25 years has shown that 
glial cells play an increasingly recognized and significant role in the functioning of a 
normal, healthy CNS.  Astrocytes serve a wide variety of roles in the brain.  Roles 
which directly help to maintain neurons include: 
 Provision of needed nutrients like lactate (metabolic support)  
 Maintenance of physical structure in the brain (structural support) 
Astrocytes also have roles that do not directly support neurons, but are necessary 
for normal brain function.  These roles include: 
 Maintenance of tight junctions at the blood-brain barrier via release of 
soluble molecules [74] 
 Control of cerebral blood flow in combination with neurons [74, 80, 134, 146] 
 Regulation of ion concentration in the extracellular space.  Neurons that are 
actively firing release potassium into the surrounding environment.  
Astrocytes have high expression of potassium channels which are responsible 
for clearing this possible excess in potassium from the extracellular space, 
particularly at the synaptic cleft. This process is necessary to prevent excess 
potassium in the extracellular space and subsequent abnormal depolarization 
(which has been shown to seizures). 
 Promotion of oligodendrocytes myelination.  Extracellular levels of ATP 
increase due to neuronal electrical activity.  In response to this, astrocytes 
secrete cytokine leukemia inhibitory factor, which in turn promotes 




 Regeneration: Astrocytes fill the void left by injured cells (a glial scar), either 
helping to repair the damage or replacing cells that cannot regenerate 
(neurons) [134]. 
 Uptake and release of neurotransmitters: Astrocytes express ATP, glutamate 
and GABA transporters for neurotransmitters at their plasma membrane.  
Recent studies have also shown that they release ATP and glutamate in 
response to calcium waves, which can alter the amount of neurotransmitter 
present in the synaptic cleft and subsequently the functioning of the synapse 
[55]. 
 Modulation of synaptic connectivity and transmission:  In the CNS, synapses 
are surrounded by astrocytes, which provide both structural and functional 
support into the functioning of the synapse.  Many of these roles have already 
been discussed above. This close 
interaction between the pre- and post-
synaptic neurons, as well as the astrocytes, 
is known as the tripartite synapse.  
Astrocytes have also been shown to have 
an influence on synaptic connectivity, 
including synapse formation, functionality, 
plasticity and eventual elimination [49, 
153].   
 The brain is an isolated system, 
relatively speaking, since a healthy, 
Figure 5: The Tripartite Synapse Model. Synapses 
are ensheathed by astrocytes, which serve pertinent 
roles in modulating neurotransmitter activity and 




functioning blood-brain barrier (BBB) prevents the passage of many molecules and 
substances that would otherwise be toxic or harmful to neurons and other neural cell 
types.  This separation implies that the brain is an “immune privileged” organ; that is, 
the brain must maintain its own immune system independent of the rest of the body‟s 
immune system.  Pathogens, infectious agents or toxic compounds that do traverse the 
BBB must be quickly and efficiently removed from the brain to decrease the 
inflammation and prevent damage to neurons.  Neurons and other cells can also be 
injured by physical injury or die of natural causes, and need to be removed from the 
brain to maintain structural homeostasis.  Microglia fill this necessary role of resident 
macrophages, protecting against invading pathogens that are capable of crossing the 
BBB, as well as clearing unwanted debris. 
 Although this is such an important role for normal brain functioning, 
microglia only compose about 20% of all glial cells in the brain.  Of mesenchymal 
origin, microglia are spread relatively uniformly under healthy conditions, and 
express a phenotype known as „resting or ramified microglia‟ [79].  Microglia move 
constantly within non-overlapping spaces, scavenging for debris and dead or injured 
cells.  Microglia engulf debris via site-directed phagocytosis.   
 They are also apt sensors of neuronal stress [8], expressing receptors and 
molecules capable of participating in a large variety of signaling pathways, 
communicating with neurons via neurotransmitter receptors, with other macroglial 
cells like astrocytes, and with macrophages and effector molecules of the immune 
system such as cytokines.  When a contagion, lesion or other CNS dysfunction is 




Activated microglia are capable of releasing a variety of molecules at high 
concentration into the surrounding environment.  These molecules can be either 
beneficial to the nearby cells, aiding in their survival, or detrimental, especially if the 
microglia remain activated for extended periods of time.  It is important to note that 
activated microglia can migrate towards a site of infection and proliferate, possibly 
increasing the local level of inflammation.  Microglia and their related role in 
neuroinflammation, have been suggested to be key players in the pathogenesis of AD. 
Neurochemistry: The importance of lipids and proteins 
Important Biomolecules: 
 Metabolism in the brain is a highly complex process, encompassing basic 
glucose metabolism for energy usage, to neurotransmitter synthesis by neurons and 
myelin synthesis by oligodendrocytes.  The main source of energy in the brain is 
glucose; however, under conditions of starvation, ketone bodies produced from fatty 
acid metabolism can also provide energy for basic cellular processes.  Regulation of 
many biochemical pathways is often tightly controlled, though can easily be affected 
by changes in plasma glucose concentrations, oxygen levels, and other hormones.  
Locally-acting molecules, such as cytokines, paracrine and autocrine hormones, and 
nitrous oxide can also have significant effects on the metabolic functions of neurons 
and glial cells.   
Although many of the metabolic pathways are highly conserved and expressed 
across various cell types, expression patterns of lipids and proteins often vary 
depending on cell type.  For example, in the adult brain, cholesterol is only 




process [12].  The basic metabolic expression profile for the brain can be broken 
down into five parts corresponding to five main types of cells within the CNS: 
neuron, astrocyte, microglia, oligodendrocyte and endothelial cell.  All cell types 
express the molecules necessary for: 
 energy-producing metabolic processes (glycolysis, the citric acid cycle) 
 transcription and translation (RNAases, ribosomes, RNA enzymes, 
ribozymes) 
  anabolic and catabolic biochemical processes (lipid and carbohydrate 
generation and degradation) 
   The expression of the remaining types of biomolecules and metabolites are 
dependent on the functional roles of the individual cell types.  For example, neurons 
have relatively higher expression patterns for neurotransmitters, neurotransmitter 
receptors, axonal and axonal transport proteins, and synaptic proteins when compared 
to other CNS cell types, and although they do have functional mitochondrial 
pathways, do obtain a large percentage of their nutrient intake from nearby astrocytes.  
Astrocytes express neurotransmitters and their corresponding receptors at a 
significantly lower levels than neurons, but high levels of potassium and calcium 
channels, ATP and GABA receptors, and produce C-LIF to modulate myelineation by 
oligodendrocytes.  They are also responsible for producing and transporting 
cholesterol to neurons in the adult brain.  Oligodendrocytes have very high expression 
profiles for lipids, particularly cholesterol and fatty acids found in cell membranes.  
Microglia express a large variety of cytokines when activated, as well as many 




necessary transport of molecules across the blood-brain barrier and for formation of 
tight junctions, as well as many others. The following figure pictorially describes how 
these pathways vary among different cell types, and demonstrates the importance of 
differences in the expression of lipidomic, proteomic and inflammatory pathways on 
the interaction between cell types. 
 
Cholesterol: 
 Cholesterol is an important steroid molecule, having diverse roles throughout 
the human body.  Its molecular formula is C27H46O, atomic molecular weight is 
386.65 g/mol and is a white crystalline solid at room and body temperature. It is the 
main sterol produced by mammals.  Only a small amount of cholesterol is produced 
by plants and fungi, while bacteria produce only trivial amounts.  The word 
cholesterol is derived from the Greek words chole- (bile) and steros (solid); the suffix 
Figure 6: Expression Patterns of Different Cell Types in the Brain. Every cell type in 
the brain is capable of maintaining its own energy-producing pathway (metabolic 
pathway), though the expression levels of various proteins, channels and lipids varies 




–ol is added to recognize that cholesterol is effectively an alcohol (hydroxyl group at 
the 3‟ carbon).  Cholesterol was first identified in gallstones in 1769 by Francois 
Poulletier de la Salle, and was later named cholesterine by Eugene Chevrul in 1815.  
The following figure shows the chemical structure 
Cholesterol is the main precursor for many very common hormones, including 
the sex hormones (progesterone, estrogen and testosterone), cortisol and other 
corticosteroids, and aldosterone produced by the adrenal gland.  Cholesterol is also 
the precursor for molecules such as beta-carotene, needed for vision; 
geranylgeranylpyrophosphate and farnesyl-PP, needed for memory and learning; and 
bile, which is produced by the liver and needed to solubilize fats in the intestine and 
aid in absorption of fat-soluble vitamins (A, D, E and K).  Cholesterol is a required 
precursor for the synthesis of vitamin D and a necessary component of cellular 
membranes.   
Within membranes, cholesterol modulates membrane fluidity in a 
temperature-dependent manner.  Increased cholesterol is believed to decrease 
membrane fluidity, while decreased cholesterol increases fluidity.  This is due 
partially to the fact that cholesterol is a lipophilic compound; polar head groups in the 
cellular membrane interact with the hydrophilic hydroxyl group of cholesterol, while 
the remainder of the cholesterol molecule interacts with the hydrophobic fatty acid 
tails of membranes.  Increased cholesterol levels in cellular membranes have also 
been shown to decrease membrane permeability to sodium ions and protons, helping 




Cholesterol has other functions within the cell.  At the cell membrane, 
cholesterol plays several roles: in intracellular transport as a required molecule for the 
formation of clathrin-coated pits and caveolae in endocytosis; in the formation of 
lipid rafts important in cellular signaling; and in the myelin sheath as an efficient 
insulator. 
The predominant sites of synthesis are the liver, the intestines and the brain.  
Cholesterol synthesized by the liver or intestines is only available to cells and organs 
outside of the CNS; the brain is responsible for synthesizing all of its cholesterol in-
house.   In the adult brain, only astrocytes are responsible for synthesizing cholesterol 
[12] since the process is highly energy-intensive.  Synthesis proceeds through a 28 
step process from HmgCoA to cholesterol.  The rate-limiting step in cholesterol 
synthesis is the conversion of HmgCoA to mevalonate; this has been capitalized on 
via the development of statins, which inhibit the action of HmgCoA reductase, the 
enzyme responsible for this conversion.  Cholesterol is also an inhibitor of its own 
synthesis (end-product inhibition); high levels of cholesterol lead to an increased 
degradation rate of HmgCoA reductase, and subsequently fewer molecules traverse 
the mevalonate pathway.  In essence, this creates a negative feedback loop between 




Cholesterol levels are tightly regulated in the body by the SREBP (sterol-
regulatory element binding protein) protein and the end-product inhibition previously 
discussed.  The SREBP pathway is important for up-regulating genes in response to 
decreased intracellular cholesterol levels, working together with the SCAP (SREBP-
cleavage activating protein) protein and Insig-1 to achieve this.  In addition to 
cholesterol end-product inhibition, cholesterol synthesis levels can be reduced when 
HmgCoA reductase is phosphorylated by AMP-activated kinases, inhibiting the 
activity of HmgCoA.  AMP levels are high when ATP levels are low, thus, if there is 
mitochondrial dysfunction or a decrease in ATP levels, cholesterol synthesis stops, 
overriding the SREBP pathway. 
Figure 7: Cholesterol Synthesis Pathway. Simplified version of the cholesterol 




Choline & Acetylcholine: 
 Both choline and acetylcholine are important biomolecules in the brain.  
Choline is an essential nutrient (intake required/body does not synthesize) that plays 
several key roles within the body.  It is one of the required precursors for 
acetylcholine production; it is important in maintaining the structural integrity of cell 
membranes and in cellular signaling pathways; and it serves as an important molecule 
in methyl group transfers via its metabolite, betaine, in the SAM-e pathway.  Diets 
low in choline are known to cause fatty liver, kidney necrosis, renal impairment, 
infertility, growth impairment, bone abnormalities and hypertension.  Choline 
deficiency can be identified by measuring liver enzyme ALT activity (increased 
levels indicate deficiency).  Other methyl group transfer molecules (B6, B12 and folic 
acid), as well as choline, are known to reduce homocysteine levels, and thus decrease 
the risk of heart disease.  Sources of choline include eggs, liver and peanuts.  Some 
vegetables also contain choline, but in significantly smaller amounts. 
Choline may also play an important role in DNA methylation, thus partially 
controlling the expression pattern of genes (epigenetics).  Phosphatidylcholine, a 
choline metabolite, is also an important precursor molecule for the arachidonate 
pathway (responsible for producing prostaglandins, pro-inflammatory molecules that 
act locally), as well as interacting with fatty acids to produce phospholipids at the 
membrane.  Changes in choline levels affect brain function, muscle function, liver 
and kidney function, and cardiovascular health in a direct manner.  Thus, there is a 
relationship between inflammation, brain health and cardiovascular health that should 




One of the most important role that choline plays within the nervous system is 
in the production of acetylcholine.  Acetylcholine (ACh) has several functions both in 
the CNS and the PNS.  In the PNS, acetylcholine activates muscles and participates in 
the autonomic nervous system as a neurotransmitter.  In the CNS, acetylcholine is the 
major neurotransmitter in the cholinergic system and is produced in neurons by 
choline acetyltransferase, an enzyme that combines Acetyl CoA and choline.  It is 
degraded by acetylcholinesterase, an enzyme that has been a key target in AD and is 
currently one of the few pharmacological treatments available (acetylcholinesterase 
inhibitor).  
ACh has important roles in plasticity, arousal, reward, sensory perception 
upon waking, attention, and in learning and short-term memory.  Experimental 
evidence has demonstrated that ACh enhances the amplitude of synaptic potentials 
following long-term potentiation (LTP).  Acetylcholine is also responsible for either 
increasing neuronal excitability or causing inhibition.  It is believed that layer-specific 
differences in the effects of ACh on neurons may help improve the signal-to-noise 
ratio of cortical processing.  This specificity of behavior is also related to the fact that 
there are two types of acetylcholine receptor: nicotinic and muscarinic.  Nicotinic 
ACh receptors are ionotropic receptors stimulated by nicotine and acetylcholine.  
These receptors are permeable to sodium, potassium and chloride, and are found in 
the CNS, the end plates of muscles and in ganglia participating in the autonomic 
system.  Conversely, muscarinic ACh receptors are metabotropic, act on neurons over 




receptors are found in the CNS, PNS, upper gastrointestinal tract, lungs, heart and 
sweat glands. 
LRP-1: 
 The low-density lipoprotein receptor-related protein 1 (LRP-1) is a key 
receptor within the brain responsible for transporting a variety of molecules.  LRP-1 
receptors are found both on endothelial cells at the blood-brain barrier, as well as on 
neurons.  At the BBB, LRP-1 transports both free and ApoE-bound beta amyloid 
basolaterally (from the brain to the blood).  LRP-1 receptors are also found on 
neurons to allow cholesterol to be transported from astrocytes to neurons in the adult 
brain.  Inflammatory cytokines, such as IL-1, are known to up-regulate the expression 
of LRP-1. 
ApoE: 
Lipoproteins serve the important role of transporting lipid-soluble molecules, 
such as cholesterol, through an aqueous environment to their target destination.  Brain 
apolipoproteins, in particular apoE, coordinate the mobilization and re-distribution of 
cholesterol and phospholipids for the repair, growth and maintenance of myelin and 
neuronal membranes [28, 110-111].  ApoE is particularly important for synaptic 
remodeling, and is expressed in astrocytes, cells in the blood vessels and choroid 
plexus, neural stem cells and injured neurons [71].  Astrocytes have been shown to 
release cholesterol bound to one of the three different apoE isoforms: ε2, ε3 or ε4.  
The affinity of the apoE isoforms as a lipid acceptor was: apoE2 > apoE3 = apoE4 in 
astrocytes, and apoE2 > apoE3 > apoE4 in neurons [99].  The pro-inflammatory 





The brain’s immune system: 
 For many years, the brain was believed to have its own separate immune 
system provided by resident macrophages (microglia) that are capable of responding 
to invading agents and toxins by phagocytosis and secretion of pro-inflammatory 
cytokines, in combination with protection from pathogens and toxins in the blood by 
the blood-brain barrier.  Under cases of extreme infection, such as meningitis, 
macrophages could be recruited from the blood to help combat the invading agent, 
but must be quickly subdued to prevent damage to neurons that are exquisitely 
sensitive to the effects of cytokines and other pro-inflammatory molecules.   
Recent research has shown that this model is not the full picture, and the 
systemic immune system in fact does interact with the brain and is capable of 
controlling behavior, neuroendocrine function, synaptic plasticity and 
neurotransmitter metabolism [24].  Pro-inflammatory cytokines, such as IL-1, that are 
produced in the periphery are capable of entering the CNS and interacting with the 
network of cytokines and microglia in the brain to effect these changes.  This can lead 
to significant changes in behavior, including insomnia, anxiety, depression, anorexia, 
psychomotor retardation and cognitive dysfunction [24].  Individuals with HPA-axis 
hyper-reactivity (over-reactive stress response) in combination with subclinical 
depression are at increased risk for developing such cytokine-induced depressive 
symptoms [23, 117]. 
Although they are capable of interacting with the brain, cytokines are not able 




have been identified, including: active transport by brain endothelial cells; 
transmission via the vagus nerve; passage through „leaky‟ areas of the blood-brain 
barrier, such as the choroid plexus, or through dysfunctional blood-brain barrier; via 
activated monocytes; and by activation of brain endothelial cells stimulating release 
of prostaglandin G2 and nitric oxide [24, 116].    Passage of cytokines through one or 
more of these routes leads to disruption of the innate cytokine network in the brain, a 
network of neurons, microglia and astrocytes capable of expressing cytokines and 
cytokine receptors, and amplifying signals within the cytokine network [62].  Pro-
inflammatory cytokines that are normally expressed in the brain include IL-1, IL-1 
and TNFα.  The signaling cascade modulated by these cytokines can be disrupted by 
peripheral cytokines, leading to activation of the HPA axis, release of corticotrophin-
releasing hormone, and alteration of serotonin, norepinephrine and dopamine usage 
[100]. 
Under normal conditions (ie. no peripheral inflammation), the levels of 
acetylcholine play important roles in maintaining the balance of pro-inflammatory 
cytokines.  Acetylcholine achieves this by binding to nicotinic acetylcholine receptors 
on microglia, activating a signaling cascade that inhibits the release of pro-
inflammatory cytokines.  This pathway has no effect on anti-inflammatory cytokines, 
such as IL-10.  
 The inflammatory pathway within the brain walks a very thin line between 
being helpful and being harmful.  Over short time periods, pro-inflammatory 
cytokines can help to remove an invading pathogen or toxin, while producing 




inflammatory cytokines lead to decreased protein synthesis, decreased cellular energy 
levels due to decreased uptake and availability of glucose for non-immunological 
cells, changes in protein and lipid expression levels, and changes in neurotransmitter 
levels.  It is this imbalance in inflammation which may play a key role in AD.  
Mechanisms of action: 
 Interleukin-1 (IL-1) is one of the predominant cytokines produced by brain 
microglia.  The roles of IL-1 in the brain are diverse and cause different effects in 
different brain regions.  The highest density of IL-1 receptors is found on 
hippocampal cells in the dentate gyrus [11].  IL-1 levels have been shown to increase 
in response to stress, sleep deprivation, and long-term potentiation via NMDA 
receptors.  Prostaglandin E2, Aβ and glutamate are also known to increase the 
expression levels of IL-1.  IL-4 and interferon-γ are known to decrease levels of IL-1.  
It is interesting to note that IL-1 enhances neuronal acetylcholinesterase activity, thus 
increasing the rate at which acetylcholine is degraded (decreasing the level of ACh), 
though it‟s production is inhibited by acetylcholine.  This in effect is a common 
network topology with a dual negative feedback loop; the overall result is a switching 
behavior reminiscent of a clock used in digital logic. 
 IL-1 is known to have a relatively strong effect on neurotransmitter turnover 
rates: in the hypothalamus and hippocampus, noradrenaline turnover rates are 
increased; in the prefrontal cortex, dopamine utilization is increased; and in the 
hippocampus and prefrontal cortex, serotonin turnover is increased.  These changes in 
neurotransmitter turnover rates may have significant effects on the functions of each 




decreasing the activation threshold for the hypothalamic-pituitary-adrenal axis 
(HPA); inhibit the hypothalamic-gonadal axis; increase the production of aldosterone; 
and cause hypoglycemia by lowering the glucose set point throughout the body. 
 Within the hippocampus, IL-1 has many of the same effects described above 
(increased acetylcholinesterase activity in neurons, same activating and inhibiting 
compounds).  IL-1 also causes increased serotonin turnover with an accumulation of 
tryptophan (the precursor amino acid for serotonin).  The amount of glucose available 
to neurons and other cell types is decreased, limiting energy production as well as 
production of proteins and lipids.  Increased levels of IL-1 that have been sustained 
for a short duration are known to stimulate the release of prostaglandins and reactive 
oxygen species into the local environment, enhancing seizure activity and increasing 
the rate of entry of calcium into cells via NMDA receptors.  
Alzheimer’s disease Pathology: 
Alzheimer‟s disease (AD) is the most common form of dementia, affecting 
more than 4.5 million individuals in the US alone [65]. This number is expected to 
increase almost 3-fold by 2050 as the number of people over 65 (the most affected 
group of individuals) surpasses 12 million. The cost of care for individuals with AD 
is staggering- over $140 billion annually, which is expected to rise in correlation with 
the number of affected individuals. The exact cause of AD is uncertain, though 
mutations in APP (amyloid precursor protein) and presenilin protein have been 
linked to early-onset of the disease. Age, the presence of the apolipoprotein ε4 allele, 




plasma cholesterol have all been linked to an increased risk of AD later in life.  The 
following table summarizes the known risk factors for AD. 
Risk Factor Cause Possible Effects 
ApoE4 allele Genetic 
Less able to transport cholesterol to neurons, 
possibly less able to transport Aβ out of brain 




Increased APP, suggested increase in Aβ 
cleavage 





Increased inflammation, decreased glucose 





Increased inflammation of body system; 
inadequate transfer of glucose 
Dysregulation in steroid 
periodicity 
Stress/lifestyle 
Alterations in inflammation, neuronal cell 
death 





Chronically increased cortisol 
levels 
Stress/lifestyle 
Increased inflammation, alterations in 
metabolism 
Decreased LRP expression Genetic, aging Decreased Aβ clearance, cholesterol uptake 
Transferrin mutation Genetic 
Decreased ability to synthesize cholesterol, 
myelin 




Reduced neuron number increases effects of 
other alterations 
Traumatic brain injury Inflammation Increased inflammation 




Alterations in Aβ cleavage rate, cellular 
metabolism; interaction with inflammation 
 
Regardless of the disease trigger, the resultant pathological characteristics are 
similar and involve the buildup of amyloid protein in the brain parenchyma and 
deposition in cerebral blood vessels (as cerebral amyloid angiopathy, CAA), as well 
as the presence of neurofibrillary tangles within affected neurons. Loss of neurons 
and synapses in the hippocampus, neocortex and other subcortical regions has been 
observed [113]. Activation of microglia (resident CNS macrophages) and 
Table 3: Risk Factors for AD. AD has several well-known risk factors, including the 
ApoE4 allele, cerebrovascular disease, and mutations in APP or presenilin I.  A combination 




neuroinflammation are also observed, as well as alterations in BBB permeability [66, 
121, 156-159]. The combination of these cellular and subcellular changes leads to the 
symptoms most commonly associated with AD, including: gradual memory loss, 
personality changes, depression, inability to communicate and loss of voluntary 
muscle movements [94]. Even with the significant advances that have been made in 
AD research, there is still no clear understanding of what the causal relationship is 
between these different symptoms, that is, what is the network connection created 
between different agents. 
AD: A gimesh of pathogenesis theories: 
The discovery of parenchymal amyloid plaques and NFTs by Alois Alzheimer 
in 1906 revolutionized the way that researchers looked at AD, providing the basis 
where many researchers begin their study.  As the wealth of knowledge on AD has 
grown significantly in the last 20 years, several different theories on the origins and 
pathogenesis of AD have emerged.  Biochemical studies in the 1980s lead to the 
discovery that the core protein in plaque deposits was beta amyloid (Aβ), leading 
many researchers to believe that the buildup of Aβ as plaques was the main causative 
factor in AD.  Further studies revealed that cleavage of the amyloid precursor protein 
(APP) by β-secretase and subsequently by γ-secretase leads to the 39-42 amino acid, 
amyloidogenic form of Aβ.  This monomeric form of beta amyloid often aggregates 
and forms oligomers, fibrils and eventually plaques.  Oligomers range from 2-100 Aβ 
peptides (1-3 nm in height by 5-10 nm in length), while fibrils are significantly longer 
and can achieve lengths ~ 200 nm [17].  Oligomeric forms of beta amyloid (<5 nm) 




Amyloid Cascade Hypothesis: 
Early experimental data points in AD research led to the development of the 
first major hypothesis for AD pathogenesis: the amyloid cascade hypothesis.  This 
hypothesis, developed by Dennis Selkoe [130], 
states that the high extracellular levels of 
soluble Aβ oligomers are toxic to neurons, 
leading to synapse loss, activation of microglia 
and an inflammatory state.  This hypothesis is 
unable to account for the fact that there are 
individuals with high brain Aβ levels that do 
not have symptoms of AD or even cognitive 
decline.  However, since most assays for beta 
amyloid do not measure oligomeric beta 
amyloid, there is the chance that plaque load 
may be increased without having a concurrent 
increase in the level of Aβ oligomers.  This 
hypothesis does a good job describing the 
pathological characteristics of AD, but does 
not describe why there is an initial increase in 
Aβ, thus, still eluding our understanding of 
what actually triggers AD.  In the familiar forms of AD, the increase in Aβ is due to a 
mutation in APP or PS1, however, this mutation is not seen in late-onset AD.   
Figure 8: Amyloid Cascade Hypothesis. 






Another early hypothesis for the cause of AD is the cholinergic hypothesis.  
Biochemical studies in the late 1960s and early 1970s revealed decreased levels of 
choline acetyltransferase, the enzyme responsible for the synthesis of acetylcholine, 
as well as reduced levels of acetylcholine release, decreased choline uptake, and loss 
of cholinergic neurons in the basal forebrain and cholinergic transmission in the 
cerebral cortex [53].  These alterations were believed to lead to the cognitive decline 
in AD since they were present in the early stages of the disease. 
Neurotransmitter dysregulation is not uniform across all classes of 
neurotransmitters, nor is it constant over time.  Initially, only the cholinergic pathway, 
and to a lesser extent, the serotonergic and noradrenergic pathways are affected.  
GABA, dopamine and somatostatin remain unaltered in early disease stages [53].  
Changes in the serotonergic pathway are thought to be more related to the behavioral 
changes seen in AD, whereas cholinergic changes are believed to be more related to 
cognitive decline.  As AD progresses, the initially affected pathways are affected 
more, while the GABA and somatostatin pathway begin to be affected [123-124]. 
Given these recognized changes in neurotransmitter levels, particularly 
acetylcholine levels, cholinesterase inhibitors (Aricept, Exelon and Reminyl) are 
currently one of the only drugs available to treat AD.  These drugs work by inhibiting 
the breakdown of acetylcholine by acetylcholinesterase, thus increasing the level of 
acetylcholine in the brain.  The only other drug available to treat AD (Ebixa) blocks 
the release of glutamate and is supposed to prevent further damage to neuronal cells 




the symptoms of AD, they are not able to stop or prevent AD pathogenesis.  There are 
also some serious side effects related to their usage, often related to over-activity of 
the cholinergic pathway in the peripheral nervous system.  Again, although there are 
some benefits to increasing the acetylcholine levels pharmaceutically, the 
cholinergic/neurotransmitter hypothesis fails to describe some of the observed 
pathology, such as increased Aβ levels and decreased brain cholesterol. 
Inflammation Hypothesis: 
Neuroinflammation is a key characteristic of AD that leads to increased levels 
of cytokines, chemokines, complement proteins and free radicals, all of which are 
detrimental to the health of neurons [102-103].  Several groups of researchers have 
proposed that inflammation plays a significant, if not also a causative, role in AD 
pathogenesis [4-5, 34, 67, 82, 98, 127-128, 156, 161].  This hypothesis has been 
supported by several different studies.  A relatively recent study by Cagnin et al used 
positron emission tomography (PET) and volumetric magnetic resonance imaging 
(MRI) in patients with mild to moderate cognitive dementia and found that microglial 
activation occurred at very early stages in the AD process [20].  Epidemiological 
studies have also shown that there is a reduction in the risk of AD if non-steroidal 
anti-inflammatory medication is taken [140-141, 151].  Lim et al provided data that 
demonstrated that treatment of AD transgenics with ibuprofen reduced the levels of 
interleukin-1β and glial fibrillary acidic protein, while simultaneously decreasing the 
total number and area of amyloid plaques [89].  It has also been shown that cognitive 
decline and suppression of long-term potentiation occur before observable plaques 




Much of this data suggests that inflammation occurs early in AD 
pathogenesis.  However, several questions still remain; in particular, even though 
inflammation occurs early in the AD process, it is not clear whether inflammation is 
the cause of neurodegeneration, what exactly triggers the inflammatory response, and 
whether it just helps to promote further neurodegeneration that has been started by a 
separate process.  There is also insufficient understanding about how amyloid plaque 
deposits in cerebral blood vessels that disrupt the blood-brain barrier may influence 
the initiation of the inflammatory process. 
 
LRP/RAGE Hypothesis: 
More recent studies have started to focus on the interplay between cerebral 
amyloid angiopathy (CAA) and the influx/efflux of Aβ at the blood-brain barrier 
(BBB).  Zlokovic et al have proposed a hypothesis that an increase in the blood-to-
brain transport of Aβ, combined with a decrease in the brain-to-blood efflux of Aβ, 
leads to Aβ accumulation in the extracellular space, as well as accumulation in the 
basement membrane of vessels as CAA [164-165].  This accumulation leads to the 
activation of microglia, amyloid fibril formation, reduction of cerebral blood flow, 
localized ischemia, degeneration of the endothelial cell wall leading to accumulation 
of metabolic waste, changes in pH, electrolyte imbalance, and eventually, neuronal 
cell death when the capillary unit collapses [165].  The changes in BBB transport are 
believed to be due to two receptors: RAGE (the receptor for advanced glycation end-
products; responsible for Aβ influx) and LRP-1 (the low-density lipoprotein receptor-




Miller et al recently conducted a study using confocal microscopy of 
immunostained hippocampi to demonstrate that RAGE receptor levels on endothelial 
cells at the BBB are in AD patients when compared to controls, and that this increase 
is approximately a linear function of the severity of AD pathology [101].  Previous 
studies have confirmed this observation, noting the strong correlation between RAGE 
immunoreactivity in the microvasculature and low immunoreactivity in neurons [36-
39, 43, 77].   
LRP-1 expression levels have also been shown to be altered in AD.  Donahue 
et al clearly demonstrated a decrease in LRP-1 expression levels in the cerebral 
microvasculature in AD hippocampi when compared to controls [43].  This data 
correlates well with Zlokovic‟s hypothesis, however, further studies are needed to 
ascertain whether the changes in LRP-1/RAGE expression levels are due to changes 
other than just aging (such as blood vessel abnormalities or atherosclerosis), whether 
cerebral amyloid deposition occurs before expression changes take place, whether 
there is a correlation between changing receptor expression levels and cholesterol, 
and whether decreased LRP-1 receptor levels affects ApoE binding and delivery of 
cholesterol to neurons and other cells. 
Cerebrovascular Hypothesis: 
One of the more recent areas of focus in AD research is studying the 
connection between lipid metabolism, cerebrovascular dysfunction and onset of AD 
[95].  Epidemiological studies have shown that several cardiovascular risk factors 
overlap with AD risk factors, including diabetes, hypertension, high cholesterol and 




atherosclerosis of the circle of Willis that lead to reduced cerebral blood flow are also 
often found in individuals with AD [122, 133].  Hemorheologic abnormalities have 
also been observed with a relatively high frequency in individuals with AD, including 
an increase in whole blood viscosity and significantly higher markings on a severity 
index for vasculopathy [132].  It is interesting to note that the apoE4 allele is one of 
the genetic links between atherosclerosis and AD [51].  An initial study into the 
relationship between AD pathology and hypercholesterolemia found that diet-induced 
high cholesterol led to an increase in the Aβ plaque load in the CNS, as well as an 
increase in the density and size of plaque deposits [118-119], however no one has 
crossed an AD transgenic mouse with a mouse strain prone to atherosclerosis.  All of 
this data seems to indicate that the large overlap between AD risk factors and 
atherosclerosis risk factors implicates the need for further study to determine if there 
is an underlying similarity in pathogenesis. 
Cholesterol Hypothesis: 
Lipid metabolism, particularly processing of cholesterol, has come to the 
forefront of AD research in the past decade.  As mentioned previously, cholesterol 
has important roles in the maintenance and survival of neurons in the CNS.  Recent 
studies have demonstrated that cholesterol levels help to regulate the generation and 
clearance of Aβ [63, 113].  The belief here is that an increase in cholesterol, which is 
seen in the blood plasma of many individuals with AD, causes an increase in the 
production and deposition of amyloid beta peptides [72, 113].  However, there is 




A recent study by Liu et al demonstrated that increasing the level of APP, 
particularly the γ-secretase cleavage product AICD, led to a decrease in LRP-1 
expression levels, an increase in apoE levels and a decrease in cholesterol [90].  
Further studies have shown that decreased brain levels of cholesterol are found in 
both apoE4 knock-in mice and in AD brains [64, 86-87].  The Framingham study 
which tracked 1894 individuals over the course of 16-18 years found that low or 
normal levels of cholesterol were correlated with lower cognitive performance levels 
[48].  This apparent contradiction between different studies may be due in part to the 
fact that under normal circumstances, the BBB prevents the transport of lipoprotein-
bound cholesterol from leaving circulation and entering the brain [12].  However, 
once plaques form in the basement membrane of cerebral blood vessels, the integrity 
and protective function of the BBB may dissipate.  Likewise, the presence of this 
contradiction highly recommends the need for further study and understanding of the 
interplay between changes in brain cholesterol levels and AD.  
One treatment method that is currently being studied by researchers is the use 
of cholesterol-lowering drugs (statins) to prevent and possible reverse damage done 
by Aβ buildup and deposition. Several studies on the effects of cholesterol lowering 
drugs (statins) have been completed in the last few years. Fassbender et al studied the 
effect of simvastatin and lovastatin on primary hippocampal neurons and mixed 
cortical neurons and found that this led to decreased levels of Aβ40 and Aβ42 [51]. 
They also observed similar results using a guinea pig model. Refolo et al expanded on 




mice expressing an AD phenotype and saw that plasma cholesterol levels, brain Aβ 
peptides and Aβ load were all decreased [119].  
These and other studies are serving as the basis for the current movement to 
treat AD with statins. Nevertheless, one of the most interesting studies to recently 
come out clearly demonstrates that reducing the levels of brain cholesterol may not 
prevent AD pathogenesis, as is suggested by previous studies. In this study, Halford 
and Russell crossed transgenic AD mice with cholesterol 24-hydroxylase knockout 
mice, creating a mutant strain that was prone to AD, as well as had a 50% reduction 
in brain sterol synthesis to find that Aβ plaque deposition did not vary statistically 
between the mutant and AD control strains [63].  Another recent study by Kölsch et al 
measured the levels of cholesterol and cholesterol precursors in the CSF and plasma 
and found that these levels were significantly decreased in AD patients when 
compared to control patients, suggesting that de novo synthesis of cholesterol by 
astrocytes within the CNS might be reduced [81]. 
More recent studies of the effects of statin treatment on AD pathology have 
shown a different picture.  Long-term treatment with atorvastatin in aged beagles did 
not lead to a change in Aβ levels [105].  In a similar experiment with beagles, long-
term atorvastatin treatment did not change Aβ levels, although protein oxidation and 
lipo-peroxidation were decreased [9].  Long-term statin treatment has also been 
shown to decrease CoenzymeQ10 levels significantly, leading to impairment in 
energy metabolism in the heart, liver and skeletal muscles [13].  Additionally, 
lipophilic statins, such as simvastatin, have been shown to increase oxidative stress 




studies have shown that statins did not improve cognitive function in the elderly or 
had only a very weak improvement on mild cognitive impairment [10, 68, 136].  
Recent epidemiological studies have also had similar outcomes.  The PROSPER 
study showed that treatment with pravastatin did not improve cognitive function; 
similar studies with atorvastatin and simvastatin showed similar results (no significant 
improvement with statin treatment; 52, 152, 155].  Only one recent study has shown 
that long-term treatment with atorvastatin led to improvement in cognitive 
functioning [137], though the constraints that were placed on the analysis were 
somewhat biased and may have altered results.   
Statin treatment is also known to have several significant side effects, 
including decreased levels of isoprenylation, decreased pro-inflammatory cytokines 
(which could be good or bad depending on the condition of the body), and decreased 
ability to learn and remember in long-term treatment [18].  Levels of farnesyl 
pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) are also decreased 
in statin treatment.  Both FPP and GGPP are necessary for correct subcellular 
localization and trafficking of intracellular proteins.  FPP is also the precursor for 
dolichol, a major membrane-anchoring molecule, and coenzymeQ10, which is 
necessary for energy metabolism.  Given all of these results, caution should be used 
when treating AD patients with statins and further studies are needed to determine the 
efficacy and safety of using statins. 





12 weeks No change in Aβ, 
decreased 24SHChol 
Serrano-Pozo et al 2010 
Simvastatin, 40 
mg/day, humans 
4 months No changes in CSF levels 
of Aβ or τ 
Carlsson et al 2008 
Simvastatin, 40 
mg/day, humans 
14 weeks Decreased phosphor-τ in 
CSF, no changes in sAPP, 







1 year No change in CSF or 
plasma Aβ 
Hoglund et al 2005 
Simvastatin, 5 µM, 
human neuroblastoma 
& primary astrocytes 
2 days No change in APP levels, 
decreased τ on astrocytes, 
increased τ on 
neuroblastoma cells 
Dong et al 2009 
Simvastatin, 4 µM, 
primary hippocampal 
neurons from rats 
2-3 days Decreased Aβ in cell 
culture medium 




5 weeks Reduced amyloidogenic 
processing 
Refolo et al 2001 
 
Role of Chronic Stress: 
 Chronic stress is generally considered a causal factor in a wide variety of 
diseases, from cancer, to cardiovascular disease, to diabetes and metabolic syndrome.  
Stress is also known to play a negative role in neurological and psychiatric diseases, 
worsening symptoms or inducing the appearance of new symptoms.  Chronic stress is 
also believed to be a negative modulator of learning and memory, decreasing the 
ability of hippocampal neurons to form and maintain long-term potentiation (LTP).    
Clinical studies of those with AD have shown that affected individuals have increased 
plasma cortisol levels when compared to controls [3].  Epidemiological studies have 
expanded on this and shown that individuals who are stressed or are more prone to 
being stressed have a significantly increased chance of developing mild cognitive 
impairment (MCI) and AD over non-stressed controls [76, 138-139, 150].  
Furthermore, both clinical and animal model studies have shown that glucocorticoids, 
the main effector molecule of stress in the brain, play a role in the regulation of APP 
levels in the brain [59, 125, 135, 154].   
Table 4: Review of statin treatments on markers for AD: Short review of some of the recent 
studies that have looked at the effects of statins on markers for AD pathology.  The most recent 
reviews in humans suggest that treatment with simvastatin leads to no changes in AD pathology 






 Steroid hormones have unique and important roles in everyday functioning of 
the body.  Steroids are produced both in relation to circadian rhythms, as well as in 
response to external cues.  Adrenal steroids, produced by the adrenal gland, are 
secreted in response to an experience, such as fear, stress, aggression or sexual 
encounter.  This includes glucocorticoids such as cortisol.  The response of these 
steroids is often reversible; however, over time and with repeated exposure, 
adaptative effects resulting from repetitive stress do appear.  These adaptive changes 
include: alterations in synaptic vesicle proteins, high-affinity GABA (γ-amino butyric 
acid) transport, neurotransmitter-stimulated cyclic AMP formation, and central 
serotonin and noradrenergic sensitivity [97].  In all cases, activation of the 
hypothalamic-pituitary-adrenal (HPA) axis occurs, which leads to increased secretion 
Figure 9: Role of chronic stress in Dementia and related disease processes: Chronic stress is known 
to play a major causal role in cardiovascular disease, cerebrovascular disease, insulin resistance (type 
II diabetes), and glucose dysregulation.  Chronically high levels of cortisol (the main marker for 
system stress state) lead to the suppression of the immune system, increasing the risk of individuals to 
acquire an illness.  Recent evidence has started to suggest the role of chronic stress in the 




of glucocorticoids into the blood.  Neural, neuroendocrine and neuroendocrine-
immunological mechanisms are activated, with cortisol and epinephrine acting as the 
main mediators. 
 Under most circumstances, allostasis is advantageous to the organism, since 
maintaining homeostasis and stability during change is a necessary precursor to 
survival.  Adaptive brain response via allostatic loading, however, comes at a price, 
since constant or fluctuating levels of cortisol and epinephrine leads to „wear and 
tear‟ and eventual damage to neurons.  Allostatic loading can be caused by several 
different events: 
1) Repeated activation by many stressful events; 
2) Failing to shut off after the challenge is removed; 
3) Or, the inability to be adequately activated, allowing other systems that are 
normally counter-regulated to become overactive (such as the inflammatory 
system). 
Allostatic loading is necessary for adaptation in the short term for maintaining 
survival and homeostasis.  However, in the long-term, this leads to significant 
changes and imbalances in the CNS, neuroendocrine and immune systems, affecting 
plasticity, brain structures, and hormonal functioning.  Allostatic loading due to 
chronic stress is particularly damaging to the hippocampus because it is the only 
region of the brain that contains glucocorticoid receptors.  Chronically high levels of 
cortisol lead to changes in synaptic vesicle proteins, high-affinity GABA transport, 
neurotransmitter-stimulated cAMP formation, and sensitivity of serotonergic and 




begin to atrophy, especially those in the CA3 region of the hippocampus.  This 
atrophy may be caused by excitatory amino acids, such as glutamate and can be 
blocked by NMDA receptor antagonists.  This is an interesting paradox: in the short-
run, adrenal steroids exert neuronal protection; in the long-run though, neuronal 
damage occurs if the allostatic response is not properly managed.  Though little data 
is currently available to support this as the main cause of AD, it is well established 
that stress can play contributory factors to many diseases, and further research is 
needed to determine what role chronic stress may play in development of AD. 
Summary: 
 This section has discussed the majority of theories about AD pathogenesis, 
covering everything from the initial theories (cholinergic hypothesis and amyloid 
cascade hypothesis), to the more recently developed theories (LRP, cholesterol and 
inflammation hypotheses).  Though each theory looks at a specific set of symptoms or 
changes in protein or lipid expression, no current theory links all of these ideas and 
observations together, or looks at the role of lifestyle factors like chronic stress, in the 
development of AD.  By bringing each of these perspectives together, the hope is that 
a new hypothesis that takes into account the role of inflammation, changes in protein 
expression, changes in neurotransmitter levels, changes in lipids and the role of stress 
and cerebrovascular disease can be formed that also appropriately maps the 
timescales of such changes, allowing for a clear understanding of AD pathogenesis 
and development of effective therapeutic treatments.  One of the goals of the systems 
biology math model developed in this thesis is to bring together all of the information 




disease from various aspects and attempting to figure out the interconnections 
between interacting pathways, be they cellular, molecular or regulatory, beginning 
this process.  The following table summarizes the current theories for AD. 
 
Theory Evidence for: Evidence Against: 
Amyloid Cascade 
Hypothesis 
- High concentrations of Aβ are 
toxic to neurons & lead to 
synapse loss 
- Aβ activates inflammation & 
reactive astrocytes 
- Unable to account for why beta amyloid 
is increased 




- Decreased levels of acetylcholine 
& serotonin observed 
- Alterations in enzymes related to 
acetylcholine processing 
- Unable to describe why Aβ is increased 
and why cholesterol is also dysregulated 
in the brain 
- Acetylcholinesterase inhibitors are 
unable to stop progression of disease 
Inflammation 
Hypothesis 
- Microglial activation observed 
early in AD 
- NSAIDs help reduce risk of 
developing AD 
- Abnormal increase in activated 
microglia 
- Does not explain why Aβ forms plaques 
in the parenchyma and the walls of 
cerebral blood vessels 
- NSAIDS cannot stop progression of AD 
LRP Hypothesis 
- RAGE expression levels increase 
with aging 
- LRP1 expression levels are 
reduced in both normal aging & 
in patients with CAA and AD 
- Aβ found in the brain is produced by 
neurons; only minor fractions are 
thought to be derived from the blood 
- Increases in RAGE expression levels are 
not unique to AD 
Cerebrovascular 
Hypothesis 
- Overlapping risk factors between 
AD & cardiovascular disease 
- Hemorheologic abnormalities 
seen frequently in AD 
- Having these risk factors does not mean 
an individual will get AD definitively 
Cholesterol 
Hypothesis 
- Epidemiological & experimental 
studies demonstrate that altered 
cholesterol metabolism occurs in 
AD 
- Cholesterol is able to modulate 
levels of Aβ 
- Cholesterol is an important 
molecule within the brain, as 
well as an important precursor 
molecule for neurosteroids 
- Interacts with the inflammatory 
pathways 
- Statin treatment is not efficacious in 
preventing AD 
- Having altered cholesterol levels, either 
in plasma or in the brain, cannot be used 
as a definitive marker for AD  
Table 5: Review of current hypotheses for AD pathogenesis: There are a variety of pathogenesis 
theories that have been developed for AD.  Many of these theories look only at one perspective of the 
disease, failing to recognize that AD is a complex disease affecting a multitude of pathways on various 
time scales.  A unified hypothesis that looks at AD from this aspect is needed to truly understand 




Systems Biology: why use math? 
 Over the last few hundred years, much of biology has been studied using the 
reductionist method; that is, taking apart the entire system and focusing on one or two 
components of interest.  Reductionism offers several advantages, including ease of 
studying function of individual proteins or other small molecules and reduction in 
system complexity to better help control for undesired system changes, there are 
however, several significant disadvantages.  One of the main problems with 
reductionism is that it has a tendency to oversimplify a complex, interconnected 
system of network such that the actual network connectivity and interacting nodes 
may be lost in the process, thus stifling the ability of researchers to fully grasp the 
overarching impact that specific proteins or molecules may have on a multitude of 
interacting networks.  This mindset, of looking at subsystems in isolation, prevents 
fully understanding system level interactions.  
For many years, the main hindering block in studying data across a wider 
scale has been the lack of methods and technologies to accurately control for cross-
system variables, as well as a minimal number of methods to accurately analyze 
biological data, which contains a relatively large amount of experimental noise and 
variation. With the advance of technology, newer methods have become available for 
studying large amounts of data across a system –level model such as microarrays, 
ELISAs and optimized Western blotting methods, opening up the avenue for a new 
form of biology, systems biology.   
Systems biology, a branch of science that combines systems-level biology 




approach.  The main goal of systems biology is to develop mathematical models to 
study various aspects of a single system function (for example, the interaction of 
molecules that individually have been known to lead to inflammation), or to develop 
models for disease processes, such as diabetes and cancer.  As of yet, very few 
systems biology models have been applied to neurodegenerative and neurological 
disorders, perhaps owing to the fact that the available methods to study the brain and 
its metabolic networks in real-time are fairly limited.  As imaging technologies 
advance and new assays are developed, this drawback may dissipate in the near 
future. 
Advantages of modeling 
 Systems biology offers several advantages over pure biology or pure math.  
By developing models that look at the interactions between various molecules and 
networks, a more complete picture of how the system works can be defined.  This, in 
turn, will help researchers develop more effective treatments for diseases and other 
ailments.  Through the enmeshed interaction between model development, network 
definition, and parameter estimation from obtained data, detailed network 
architectures can be developed. 
 Systems biology also offers several advantages over conventional biological 
techniques.  One of the most commonly used techniques in biology to study the effect 
of different compounds or try to understand regulation is cell culture.  Although cell 
culture is simple and easy to test many hypotheses, the results fail to allow 
researchers to view the interaction of one cell type with other cell types, and thus, the 





 One of the main drawbacks to systems biology is the complexity of networks 
that are often obtained from data analysis require significant understanding of a 
variety of metabolic and regulatory networks, a task that is not easy to achieve for 
many people and at times, may seem overwhelming.  Another drawback is that data 
obtained from microarrays, ELISAs and Western blots carries a very high margin of 
noise, often with the signal-to-noise ratio approaching one [6].  This can lead to 
development of inaccurate network topologies or incorrect parameter estimation, 
which would severely affect downstream model estimations.  Further work on the 
development of mathematical tools to analyze such data would help to prevent this.  
A final drawback is that many networks contain dozens to hundreds of nodes, and an 
order or more number of interacting edges, which makes most models 
computationally intensive to model and require significant computing resources to 
achieve relevant model simulations without simplification of network topology. 
Previous models pertaining to AD 
 Although a relatively new approach to studying AD, several models have been 
developed to study various aspects of the AD disease process.  The earliest models 
studied the kinetics of beta amyloid fibril formation using data and rate constants 
obtained from experimental work [91, 107].  Later models started to look at the 
interactions between genes that have been linked with AD, such as ApoE, and the 
interactions between different cell types.  Macdonald and Pritchard developed a 
detailed Markov model that uses epidemiological data to derive rate constants for 




an individual carrying the ApoE gene.  The main goal of this model was to determine 
the expected long term care costs associated with patients having AD. 
 More recent models have started to look at the roles of microglia in the AD 
disease process.  Edelstein-Keshet and Spiros developed a model that studied the 
development of Aβ plaques in silico, which included the involvement of 
inflammation by microglia, effects of cytokines on neurons and a role for astrocytes 
in the disease process [46].  Luca et al developed a model describing the aggregation 
of microglia in AD in response to increased levels of Aβ, performing a stability 
analysis on their system of equations and suggesting that stochastic differences in 
cells may lead to the development of senile plaques [92].  Only one recent paper, 
which has some striking similarity to our work, has been published that uses a 
network model to study the role of cross-talk between neurons, microglia and 
astrocytes [114].  A literature review showed no systems biology models had been 
developed to study AD.  Thus, the network systems biology model described herein is 




Chapter 3: Starting Point: A systems biology model of 
Alzheimer‟s disease incorporating spatial-temporal distribution 
of beta amyloid 
 
Introduction and Model Goals: 
 As described in the background section, AD has many possible causative 
culprits: A, cholesterol, ApoE, LRP-1, amongst several other contenders.  To study 
the role of each of these molecules, an initial model was developed to simulate the 
spatial-temporal distribution of beta amyloid within a region of the brain.  The model 
looked at generation rate of beta amyloid by neurons within the hippocampus and 
mapped the change in beta amyloid distribution with respect to time and location.  A 
McCulloch-Pitts model was modified to study how neuron number changed over time 
dependent on the A concentration level.  A network that describes the interaction 
between astrocytes and neurons during cholesterol synthesis in the brain was also 
modified from one found in the literature to include possible interactions of 
cholesterol with APP processing.   The initial goal of this model was to study the 
relationship between APP, A and cholesterol processing in the brain, with particular 
emphasis on the effects of low brain cholesterol and LRP-1 expression levels in the 
initiating phases of AD and neurodegeneration.  Although this was not accomplished 
with this version of the systems biology model, the framework was laid for the 
development of future model versions.  This was the only model developed that 




distribution was rather trivial if we were focusing on the hippocampus and more 
specifically, the CA1 region. 
Local Network for A & Cholesterol Processing in the Adult Brain: 
 As discussed in the background, beta amyloid is believed to be the causative 
factor in AD given its increased concentration levels in the brain in individuals with 
AD, as well as it‟s predominant presence in amyloid plaque deposits in both the brain 
parenchyma and cerebral vasculature. The amyloid precursor protein is cleaved in a 
two-step cleavage process by -secretase and subsequently -secretase to form A.  
Alternatively, APP is cleaved by -secretase to form non-amyloidogenic sAPP.  
Both sAPP and A are expressed during normal conditions and are believed to play 
key roles in neuronal excitability, enhanced synaptic plasticity, learning/memory and 
development, response to neuronal injury, and synapse formation, respectively. 
 In the adult brain, cholesterol is produced by de novo synthesis by astrocytes, 
with subsequent transport via lipoproteins and uptake by neurons.  Oligodendrocytes 
are also capable of producing their own cholesterol, but were not studied in this 
model.   Astrocytic cholesterol synthesis proceeds through the same pathway that is 
seen in other cell types, proceeding through an energy-intensive process that starts 
with Acetly-Coenzyme A and finishes with cholesterol.  Cholesterol is then packaged 
into ApoE, the main lipoprotein in the brain, transported out of astrocytes via the 
ABCA1 receptor and shuttled to neurons.   
At the neuronal membrane, cholesterol-laden ApoE binds to LRP-1 and 




cholesterol plays a role in APP processing.  Excess cholesterol or aged cholesterol is 
degraded via action of the CYP46 cytochrome, which processes cholesterol to form 
the brain-specific end product, 24S-hydroxycholesterol (24SOH).  24SOH is 
transported out of the brain and can then be transported across the BBB to the blood 
to be cleared from the brain.  It has also been suggested that a portion of the 24SOH 
is transported back to astrocytes to help modulate cholesterol synthesis, since tight 
regulation over neuronal cholesterol levels is absolutely necessary for normal 
neuronal function.  The following figure describes this process in visual detail. 
 
Derivation of the Reaction-Diffusion Equation for A Distribution: 
 In AD, the most severely affected regions of the brain are the hippocampus, 
the amygdala and the cerebral cortex.  Given that the hippocampus is the initially 




affected brain region and is also known to play a role in memory, this model focuses 
on the distribution of A in the hippocampus. A deterministic model was chosen 
following calculation of the number of beta amyloid molecules within both healthy 
individuals and individuals with AD.  Briefly, the volume of the hippocampus can be 
approximated as 6 cm
3
 [22].  Assays of the total brain beta amyloid in healthy and 





 molecules of A.  Thus, for the case of a single 
neuron or small group of neurons, a statistical model would be adequate, however, in 
the case of larger sections of the hippocampus, such as the CA1 region which we are 
interested in studying, a statistical model becomes intractable given the inefficiency 
of simulation.  This potential difficulty was overcome by using a reaction-diffusion 
equation (RDE) to model A distribution: 
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where c is the concentration of beta amyloid, DAB is the diffusion coefficient of Aβ 
and Ri represents the reactions that occur within the control volume.  The reaction 
term, Ri, can be expanded to account for beta amyloid production by neurons, 
degradation by proteases, fibril formation and uptake by microglia respectively as: 
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The first term represents beta amyloid production, which occurs only in the cell body 
of neurons.  The location of each neuron is represented by a delta function (point 
source), while the production rate of beta amyloid, , is given by a Poisson 
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 Beta amyloid production if also dependent on: the extent of inflammation, the 
general stress level, and on whether neurons are recovering or remodeling.  
Degradation by proteases depends on the reaction rate, , the A concentration and 
the concentration of insulin-degrading enzyme (IDE).  A simplified model for A 
fibril formation is described where the two rates constants, 1 and 2, represent the 
attachment of beta amyloid monomers onto an oligomer or fibril and the initial 
formation of an oligomer, respectively.  The rate of uptake by microglia, given by , 
is dependent on the beta amyloid concentration.  The location of microglia is defined 
by a delta function for simplicity in modeling. 
 A key player in the overall dynamics of the model is the flux rate of beta 
amyloid across the blood-brain barrier (BBB).  Clearance of A from the brain occurs 
either by direct transport of beta amyloid via the LRP-1 receptor, or more commonly, 
by the transport of ApoE-bound beta amyloid.  Net flux is given as the sum of active 
and passive transport across the BBB, where active transport requires some source of 
energy (ATP, GTP, etc) to transport a substance, while passive transport often occurs 
down a concentration gradient or by molecules that are easily diffusible through cell 
membranes (lipophilic molecules).  A simplified version of the Kedem-Katchalsky 
equations were used to model passive transport of beta amyloid; physically, passive 
transport of A can be likened to leakage across a semi-permeable BBB.  Passive 
transport occurs only in late stages of AD beta amyloid plaque deposition (cerebral 
amyloid angiopathy, CAA) or inflammation of the neurovascular unit leads to 




we are trying to study, passive transport contributes only a trivial amount of A 
clearance from the brain. 
 Active transport has been modeled as the major contributor to A clearance 
during the initial stages of AD.  To model this interaction, we assume that A must 
first be bound to the ApoE molecule, then diffuse through the brain parenchyma 
before reaching the BBB.  At the BBB, A-ApoE molecule must bind to the LRP-1 
receptor, which will subsequently transport the A across the BBB, while ApoE is 
recycled to the cellular surface for re-use.  Binding kinetics between the A-ApoE 
complex and LRP-1 have been modeled using Michaelis-Menten kinetics: 
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where Rmax is the maximum rate of reaction, KM is the Michealis constant and c 
represents the concentration of Aβ within a narrow boundary region around the BBB.  
The net reaction rate is also dependent upon the rate at which Aβ binds to apoE to be 
transported and on the density of LRP1 receptors along the BBB: 
      (,    - ,    - ,        -) 
For our model, the role of LRP1 to the reaction rate will be written as a ratiometric 
coefficient, L, where L ranges from 0 to 1 as follows: 
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The rate at which apoE and Aβ bind is defined macroscopically as: 
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The total flux of Aβ across the BBB is described by the reaction rate (Rs) and the total 
cross-sectional area of BBB that we are studying: 




Experimental values for the Michaelis constant and the Rmax for Aβ40 were derived 
by Shibata et al to be 15.3 nM and 70-100 nM, respectively [131].  Values for Aβ42 
are not necessary since LRP-1 predominantly transports the 40 amino acid length 
protein as opposed to the 42 amino acid form of Aβ.  Additionally, Aβ40 is the form 
found in cerebrovascular plaques, so we have assumed that this will be the form 
localized near LRP-1 receptors. 
Derivation of Aβ Diffusion Coefficient: 
The diffusion coefficient for Aβ (DAB) moving through brain tissue is not a 
readily available parameter due to the difficulty in obtaining accurate measurements.  
To overcome this, DAB was calculated using a combination of the Stokes-Einstein 
equation and a previously described method [70].  The effective diffusion coefficient 
through brain tissue can be given by: 




where D is the theoretical value for the diffusion coefficient given by the Stokes-
Einstein relationship in a fluid medium free of any obstacles and λ is the tortuosity, or 
the average hindrance of a complex medium relative to an obstacle-free medium.  In 
the brain, λ is typically ~1.6, though this value can increase during insult or stress to 
the brain, decreasing the effective diffusion.  The Stokes-Einstein relationship is: 
  
   
    
 
 
where kB is the Boltzmann constant (1.38e-23 J/K), T is the temperature in Kelvin 




of Aβ (estimated as 2 nm, [30]). Substituting these values into the given equations 





Modeling Microglial Movement through the Brain and Uptake of A 
 As discussed previously in the background section, the CNS maintains it‟s 
own immune system separate from that of the rest of the body, partially due to the 
presence of the BBB.  CNS macrophages, known as microglia, are distributed 
relatively uniformly throughout the brain during healthy, resting states.  During 
disease, microglia become activated, take on a ramified form and migrate towards the 
site (or sites) of infection, releasing pro-inflammatory cytokines and phagocytosing 
invading cells or material. 
 The movement of microglia within the brain has been modeled parametrically 
and depends on whether the microglia are activated or ramified (resting).  Ramified 
microglia are modeled using a simple random walk along a continuous plane: 
                   ( ) 
where xc is a matrix that tracks the position of the center of mass of each of the i
th
 
microglia at time t, and ξ(t) is Gaussian white noise with the constraint that the center 
of mass of two microglia cannot be less than 2R (R=microglial radius) distance from 
each other at the same time point (microglial aggregation only occurs in the activated 
state).  Microglia are assigned initial positions prior to running the simulation.  
Ramified microglia have several other constraints: microglia do not traverse the BBB 
and are confined to brain tissue; and under extreme circumstances, macrophages in 
the blood may cross into the brain and differentiate into microglia.  Microglia can 
switch to the activated state once a specified threshold difference has been exceeded.




microglia become activated and migrate up the concentration gradient towards the 
main source of Aβ.  Experimentally, this has been shown to occur near neurons or 
near the basement membrane of blood vessels.  The directed movement of microglia 
towards a chemoattractant (chemotaxis) has been modeled using the Langevin 
equation of motion: 
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where xc represents the position of the i
th
 microglia at time t,  ϕ represents the Aβ 
concentration gradient, ξ represents Gaussian white noise that the microglia would 
experience during chemotaxis, α is a positive constant that describes the strength of 
chemotaxis (α = 1 for our simulations), and κ describes whether it is positive 
chemotaxis (κ = +1; value used for our simulations) or negative chemotaxis (κ = -1). 
Neural Network Model for Neurons: 
 Neurons were modeled using a modified McCulloch-Pitts model previously 
developed by Butz et al [19].  The network is defined by several variables: N, NE, C, 
θ, Φ and β. N represents the number of logical neurons, NE is the number of 
excitatory neurons (1 to NE are excitatory, while NE to N are inhibitory), C is the 
NxN matrix of connections between neurons, θ is the common threshold of all 
neurons, Φ is the relative weight of inputs from inhibitory neurons, and β is the noise 
level in the threshold function.  The state of the network at any given time, t, is 
defined by the vector z
t
: 
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The network connectivity matrix is defined as: 
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where ci,j is the strength of the connection from neuron j onto neuron i.  From a 
biological standpoint, C represents the probability for synaptogenesis between two 
neurons (Butz 2006).  The membrane potential for neuron i is: 
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The probability of neuron i being active in the next time instant is governed by the 
threshold potential (θ), the actual membrane potential (MP), the noise level (β), and 
the percentage afference (α) as: 
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The percentage afference models the shift in the probability of firing, and is 
related to the relative levels of Aβ.  Changes in network connections are modeled by 
updating the connectivity matrix at each time step with respect to changes in pre- and 
post-synaptic elements.  Decay of pre- and post-synaptic elements is proportional to 
the strength of existing connections and the relative level of Aβ. Pre-synaptic 
elements that are connected to a post-synaptic element that is lost are able to 
recombine and form a new synapse in future time steps, whereas the „lost‟ post-
synaptic element is removed from the post-synaptic pool.  Free pre- and post-synaptic 
elements are updated to account for synaptic losses, recombinations, and 
strengthening of existing contacts.  The number of possible contact offers is 
dependent on the number of free contacts that a neuron contributes to the network. 
 The number of neurons in the network is varied during the simulation 
depending on the neuronal activity level, as well as the local concentration of beta 




with apoptosis occurring above a maximal beta amyloid concentration.  Calcium   
previously determined that a neuron‟s activity level should remain between 
0.25<si<0.85.  The neuron number in the system at a given time point is defined by a 
vector of N elements given as: 
         {
                                  
    (   )        
                                  
                              
 
Chapter Conclusion: 
In this chapter, we have discussed the initial approach that was used to model 
pathogenesis of AD. A reaction-diffusion equation was used to model the spatial-
temporal aspects of A distribution within the CA1 region of the hippocampus.  No 
effect of geometry was studied, aside from the total volume of CA1.  A deterministic 
method was chosen since the expected number of beta amyloid molecules, even in a 
healthy brain, is greater than 10
15
.  Equations for the diffusion coefficient and key 
reaction rates were derived.  Movement of microglia was modeled as a random walk 
along a continuous plane, while the number of neurons was described by a modified 
McCulloch-Pitts model.  Simulations of this model were not run for several reasons: 
difficulty of implementing an appropriate algorithm across such a variety of modeling 
modalities; lack of pertinent rate constants or values needed to iteratively solve the 
RDE; and the subsequent belief that the spatial distribution of A was relatively 
trivial in the actual initiation of the disease process. To overcome these issues, a 
network  model was developed that looked at this problem from a more systems level 




Chapter 4: What do Networks Have to do with AD?  An Initial 
Network Model for AD 
 
Introduction & Model Goals 
AD is a multi-faceted disease most likely caused by the interaction of several 
simultaneous dysfunctions.  In recent years, a large interest has been put on 
understanding the possible role of cholesterol in AD pathogenesis.  
Neuroinflammation has also been suggested to play a key role in disease progression.  
Although several experimental trials with statins and epidemiological trials measuring 
plasma and brain cholesterol have been undertaken, results have been relatively 
inconsistent.  Some of these inconsistencies may be due to hidden factors: biological 
pathways that may be interacting in previously unsuspected manners.  Given the 
inherently high-connectivity and cross-reactivity and regulation existing between 
many biological pathways, a network-based mathematical model would help to 
elucidate some of these underlying interactions, not only by helping to visualize and 
fully list the entirety of all known and suspected interacting pathways, but to also 
provide a method to discover how pathways currently thought to be unrelated may 
contribute or play a role in disease progression, as well as to study how these 
interactions change over time as the system moves from a healthy state to a disease 
state. 
 Systems biology provides a nice format to develop such a proposed model, 
bringing together data from biological experiments and simulation results from 




interacting parts at multiple levels of interaction (molecular, cellular, tissue, organ, 
body).  To achieve this notion, an initial network describing the interactions between 
the metabolic, lipidomic and proteomic networks was developed. One of the main 
goals of this model, and all subsequent models, was to study the role of cholesterol in 
AD pathogenesis since a growing body of literature has suggested the cholesterol 
levels in both the brain and plasma may play roles in disease progression.  Within the 
plasma, experimental results generally seem to concur that high plasma levels of 
cholesterol is a risk factor for developing AD; however, the exact role of cholesterol 
in the brain with respect to A production, transcription of other proteins, metabolic 
pathways and induction of inflammation are not well understood.   The following 
figure describes the possible regulatory interactions between A and cholesterol. 
 
This simple network model represents the first known attempt to study AD 
from a systems biology approach.  The network derived here consists of 6 high level 
Figure 11: Possible regulatory interactions between cholesterol and beta amyloid.  Green 
arrows correspond interactions that increase the production rate, while red lines with the 




nodes: 5 nodes representing the various cell types present in the brain and a single 
node representing the brain extracellular matrix.  Each cellular node contains an 
interconnected sub-network representing the biomolecular pathways specific to that 
cell type.  Sub-networks are capable of interacting and influencing each other, leading 
to changes in the weights of sub-network nodes.  Basic simulations were run using 
Matlab, demonstrating a key role for regulation of beta amyloid generation by 
cholesterol inhibition.  Further simulations also looked at the role that LRP-1, apoE, 
cholesterol transfer rate between astrocytes and neurons, and the effect of sinusoidal 
cholesterol inputs on the concentration of APP and Aβ. 
Hierarchies of Networks in Biological Systems 
One way of quantitatively thinking about diseases is to view them as aberrant 
networks.  In this manner, any given organism can be represented as a hierarchy of 
interacting networks, from the biomolecular-level all of the way to the organism-
level.  Networks interact within their respective hierarchal level, and can also interact 
with other levels.  Take, for example, energy production in multicellular organisms.  
At the cellular level, mitochondria are responsible for producing sufficient ATP to 
keep cellular processes running smoothly (biomolecular to cellular level interactions).  
In turn, mitochondrial output is also controlled by the local environment (whether the 
cell is being attacked by pathogens, whether local oxygen and nutrient levels are 
normal, etc); by usage demands (whether the cell is resting or in an active state, such 
as a muscle cell during exercise); and by cross-talk between other organs or the 
external environment via release of hormones, other signaling molecules and 




 These hierarchies are important to understand and take into account when 
modeling biological systems. One of the key properties that hierarchal network 
structures convey to a system is a time delay between input signal at one level and 
response at another level, analogous to that seen in control systems with feedback 
loops.  This is an important feature that is indeed observed in biological systems.  For 
example, if one were to look at what seems to be a relatively simple system process to 
model such as ingesting a meal, it would quickly become obvious that many different 
organs are involved and affected.  Simply the thought of having food when one is 
hungry causes salivation (activation of salivary glands in response to “hunger 
sensations”).  Downstream, muscles in the face and throat are used, enzymes are 
released by the salivary glands, pancreas and liver to digest food, hydrochloric acid is 
produced and released by cells lining the stomach, sodium bicarbonate is released by 
cells in the small intestine, receptors all along the intestines absorb broken down 
nutrients and water, the kidneys and liver filter absorbed nutrients to remove wastes 
or unnecessary nutrients, intestinal smooth muscle is activated to maintain peristalsis, 
and finally, the anal sphincter is contracted to expel solid waste (liquid wastes pass 
through the urethra).  This very simple process activates a multitude of system levels 
in the body, from cellular to organ, all working in unison to achieve a final goal, but 
uniquely to achieve their specific part in the process, while also initiating several time 
delays between different levels to maintain the proper feedback regulation and 




In essence, many biological processes encompass a basic pattern of interaction 
between biochemical networks, proteomic networks and genomic networks.  The 
genome provides the basic outline for what proteins are transcribed and translated, 
while epigenetic material (RNA, histones, DNA methylation) controls the finer 
details of how the organism responds to the environment through modification of 
protein transcription.  It has been suggested that genetic networks can be modeled 
with Boolean or digital logic approaches, with switches and multi-input gates leading 
to convergence along key regulatory pathways.  In turn, the proteins produced interact 
with other cellular structures to maintain the biochemical pathways necessary to keep 
the cell alive and functioning via enzymatic reactions, catalysis, transport of 
precursors from the extracellular space into the intracellular space via transporters, 
receptors to respond to the environment, and cytoskeletal proteins.  Proteomic 
networks can be modeled with a combination of Boolean logic, network theory, and 
Figure 12: Basic Interaction Pattern Between Heirarcheal Networks: The three basic pathways that 
interact within any given cell are genomic, proteomic and biochemical networks.  Each network can be 
modeled using a variety of approaches, though most commonly, genetic networks are modeled using 
Boolean logic, while proteomic networks are modeled using a combination of network theory and 




chemical rate kinetics.  Biochemical networks, running in the background, form many 
of the basic components necessary for the formation and function of a cell: ATP, 
lipids, cholesterol, carbohydrate side groups, and specialty molecules.  Chemical rate 
kinetics and Michaelis-Menten kinetics are two of the most commonly used methods 
to model biochemical networks.  With all of these networks and processes running 
simultaneously, one could easily imagine that the cell is like a mini-computer and the 
different interacting pathways are the run-time stack, microprocessor and bus. 
Diseases as System States 
 If we look at the many biological processes „running‟ in a given organism, a 
unique idea that comes to mind is the convolution of each of these processes into an 
overall net process, or state of the system.  That is, the state of a biological organism 
can be described by the sum total of the various genomic, proteomic and biochemical 
pathways that are currently being expressed by that organism.  This varies from 
phenotype, which has more to do with how the genetic and proteomic pathways 
interact to form certain physical or behavioral characteristics, with little regard to the 
role that biochemical pathways can provide feedback and indirectly modulate the 
phenotype (ie. environmental or nutritional factors). 
 The concept of an organismal state can be expanded to help differentiate more 
quantitatively the differences present during health and disease.  Assume that 
initially, each organism starts in a healthy state i, where all pathways are interacting 
as expected and expression levels are also at the expected values.  Over time, external 
influences, responses to the environment, oxidative stress and other stimuli cause the 




of a perturbed network that is operating less efficiently.  There is a range of healthy 
states that are possible for a single organism to take one; that is, small deviations in 
the expression level or interaction between pathways lead to only minor changes in 
the system, which, as a whole, can adjust to such a perturbation.  However, as enough 
of the networks become perturbed, expression and concentration levels slowly begin 
to deviate from the expected range, which leads to downstream consequences in other 
network topologies.  This is the suggested beginning of many disease processes.  The 
system may attempt to compensate initially, but if the external stimulus (environment, 
stressor, etc) is not removed or its effect ameliorated, the system converges to an 
alternative steady state, where pathways are running non-optimally, alternate 
pathways may be activated, and eventually networks must adapt and concentration 
levels change. 
From a mathematical standpoint, the state of the system can be represented 
using two matrices: one matrix which represents the current concentration levels of 
all molecules of interest (MOI), and a second matrix which represents the level of 
interaction between two given MOI.  MOI can be protein products, enzymes, lipids, 
cytokines or any other molecule involved in a proteomic, lipidomic or metabolic 
pathway.  To simplify our model here, genomic data has not been included, though 
future models will look at this to be more accurate.  The interaction matrix can 
change over time to reflect inherent changes in the system interaction and changes in 
network topology that may occur.   
This setup is very similar to a Markov process and in many ways, the state of 




space.  The state is Markovian because the future state of a complex biological 
network depends only on the current state.  It does not matter how the system reached 
the current state, only that it is at the current state; that is, the current state is pathway 
independent.  This implies that various, differing inputs can lead to a similarly 
convergent output or end result.   
Logically, this follows closely to what is seen in biological systems.  Take, for 
example, the activation of beta cells in the pancreas (responsible for producing 
insulin).  When these cells receive the appropriate input stimulus (high blood glucose 
levels), they begin producing and releasing insulin.  Assuming that there is not a 
malfunction in the control system regulating this as in diabetes, beta cells will not 
have any memory of previous times that they were stimulated to produce insulin.  
Another logical point to make here is that the Markovian memoryless property fails 
when the frequency of input signals passes a threshold.  In this case, there is not a 
sufficient time delay to allow the system to recover from the applied input and input 
signals begin to „merge‟ with each other, causing the system to shift states. 
Alternatively, the interactome of a biological system can be represented by a 
set of differential equations that describe the interactions between various molecules.  
This is somewhat easier to model over well-defined time steps, however, the main 
drawback is the need for having rate constant data and other parametric constants 
available to make the model results most accurate.  A system of differential equations 
is also a direct application of graph theory and can be expanded to include a bipartite 
structure; in effect, this graph theoretic approach represents the interactome of 





 The networks described in the last section have been simplified and 
normalized to those that would be expressed across the various cell types within the 
brain.  At the cellular level, networks in neurons, astrocytes, microglia, 
oligodendrocytes and brain endothelial cells are important to model, as well as their 








In deriving the system of equations to describe the network topology that we 
have given, several key assumptions were made.  Abstracting the network to the 
higher hierarchy (from intracellular to cellular level), we see that each cell of a given 
cell type (neuron, microglia, astrocyte or brain endothelial cell) has a similar 
biochemical and proteomic network to neighboring cells of the same cell type, with 
minor variations existing between cells within a local vicinity.  This is true because 
all cells have the same genetic background, and cells of the same type exposed to the 
Oligodendrocyte 
Figure 13: Interaction Graph Between Different Cell Types in the Brain: Directed graph 




same local environment should have similar epigenetic material, as well as activation 
of similar proteomic and biochemical pathways.  This implies that single or small 
groups of aberrant cells do not have a distinct effect on the system as a whole, and are 
often removed via apoptosis.  Within the brain, it is reasonable to assume that besides 
synaptic transmission and paracrine signaling of hormones from the HPA axis, there 
is minimal, direct chemical cross talk between metabolic pathways (glycolysis, lipid 
metabolism, etc) in neurons.  This implies that the biochemical network between 
neurons is independent from each other, allowing us to represent each cellular node 
within the cellular network as a sum of all biochemical pathways being expressed by 
that cell type.  This sum can be described by a sample distribution given by: 
 









Taking these ideas into account, two unique systems biology models were 
developed to study the role of cholesterol in AD.  The first model was developed to 
study the role of negative feedback regulation in the mixed lipidomic-proteomic-
metabolic pathway, while the second model was developed to help ask several 
questions: (1) What are the key nodes and regulatory points in the described network? 
(2) Does inhibition of BACE activity by cholesterol fit with the known data? (3) How 




 A topological network describing the interactions between the simplified 
proteomic, lipidomic and metabolic pathways has been derived for both models 
(Figure 13).  The network was simplified to include only those molecules that are 
most relevant from a biological standpoint and directly relevant to the questions that 
we were trying to ask.  In the first network, there are 10 molecules of interest in the 
network and 11 rate constants associated with the model.  There is no 
compartmentalization of the model equations into different cell types, and limited 
data exists for the rate constants.  Therefore, the rate constants were approximated as 
fractions of molecules that would interact within the defined time step. 
The second model includes compartmentalization and thus an increase in the 
number of molecules and rate constants; there are 15 rate constants and a total of 17 
molecules in this network.  The degree of each major node was calculated and is 
listed in Table 6.  All molecules are assumed to reside in one of two compartments: 
the brain (limited concentration levels) and blood (infinite sink for any molecule 
being transported across the BBB).  Within the brain, the cholesterol was subdivided 
between astrocytes and neurons, while the ApoE pool was subdivided into astrocytic 
and free ApoE.  Rate constants in this model were also approximated as the fraction 
of molecules interacting per time step and fitted to maintain a stable simulation 
environment. 
Model 1 Network & Equations 
 
 A simplified network encompassing the molecules pertinent to cholesterol and 
Aβ production was developed.  The network consists of 10 molecules (only 8 




fatty acid levels are not tracked), 7 reaction edges and 3 regulatory edges (negative 








 Acetyl coenzyme A (AcetylCoA) is produced from the action of pyruvate 
dehydrogenase (PDH) on pyruvate, and is itself the precursor to both the cholesterol 
and fatty acid synthesis pathways (HmgCoA and MalonylCoA respectively).  
AcetylCoA generation is believed to be at least partially inhibited by beta amyloid 
[66].  
 
where kβ is the strength of inhibition and is dependent on the concentration of beta 
amyloid, k5 is the rate of AcetylCoA degradation, kcholkT is the ratio of AcetylCoA 
Figure 14: Network topology for model 1 network demonstrating the interactions that 
exist between the cholesterol production and Aβ generation pathways.  This model was 
developed to study the role of negative feedback inhibition in the level of Aβ, particularly 
by cholesterol since this exact regulation is not well understood.  No 




that is converted to HmgCoA, kγ is the strength of inhibition provided by cholesterol 
on own synthesis (end-product inhibition), and kFAkT is the ratio of AcetylCoA that is 
converted to MalonylCoA and other fatty acids.  From AcetylCoA, both HmgCoA 
and MalonylCoA are produced.  The rate of this production is dependent on several 
factors, of which the concentration of both cholesterol and fatty acids is accounted for 
when the system decides to choose one pathway over the other: 
 
The cholesterol pathway is then simplified to include only mevalonate and cholesterol 
production.  The rate limiting step in cholesterol production is HmgCoA to 
mevalonate, which is regulated by the current level of cholesterol in the cell via the 
SREBP/SCAP pathway.  For simplification sakes, it has been assumed that all 





Lastly, beta amyloid levels were modeled as a function of APP concentration, with 






Model 2 Network & Equations 
 The second model presents the first-ever systems biology model used to study 
the role of cholesterol in AD.  This model was developed to help ask several 
questions: (1) What are the key nodes and regulatory points in the described network? 
(2) Does inhibition of BACE activity by cholesterol fit with the known data? (3) How 
does varying the expression levels of LRP-1 alter steady state levels of Aβ? 
 A topological network describing the interactions between the simplified 
proteomic, lipidomic and metabolic pathways have been derived (Figure 14).  The 
network was simplified to include only those molecules that are most relevant from a 
biological standpoint and directly relevant to the questions that we were trying to ask.  
There are 15 rate constants and a total of 17 molecules in the network.  The degree of 
each major node was calculated and is listed in the table.  All molecules are assumed 
to reside in one of two compartments: the brain (limited concentration levels) and 
blood (infinite sink for any molecule being transported across the BBB).  Within the 
brain, the cholesterol was subdivided between astrocytes and neurons, while the 
ApoE was subdivided into astrocytic ApoE and free ApoE. 
 A system of non-linear differential equations was developed to represent the 
described network.  The majority of metabolic reactions were described by direct 
conversion rates from precursor to product molecule.  Inhibitory interactions within 
metabolic reactions or between metabolic, proteomic or lipidomic sub-networks were 
described by Michaelis-Menten-like rate kinetics.  Neuronal cholesterol levels were 
maintained at a constant value throughout simulations via feedback control.  This 
feedback mechanism also affected cholesterol levels in astrocytes, the level of ApoE 




astrocytes, demonstrating the highly interdependent nature of cholesterol and ApoE 
concentrations in different cell types within the brain.  The following sections 
describe these equations in further detail. 















Figure 15: Network topology for mixed proteomic-lipidomic network to study AD. 
Precursor molecules (green boxes), lipidomic molecules (orange), and proteomic 
molecules (blue, purple and red) are described.  Inhibitory interactions are given by a 
red line with a blunted bar, metabolic reactions between precursor and product are 
described by solid black lines, and binding interactions between molecules are given by 
dotted, black lines. Table (right inset): Degree of Key Nodes.  AcetylCoA has the 
highest degree, followed by cholesterol.  Acronyms used: APP: amyloid precursor 
protein; ApoE: apolipoprotein E; AICD: APP intracellular domain; Aβ: beta amyloid; 
CTF: C-terminal fragment; HmgCoA: 3-hydroxy-3-methylglutaryl-coenzyme A; LRP-
1: low density lipoprotein receptor-related protein; PDH: pyruvate dehydrogenase; 





 Metabolic interactions encompass all interactions represented by green boxes 
in Figure 14.  AcetylCoA is generated from pyruvate via action of pyruvate 
dehydrogenase (PDH).  The rate of this reaction has been shown to be influenced by 
the concentration of Aβ [66].  Since the concentration of PDH is believed to be 
constant during AD, the rate equation was modified to be independent of PDH 
concentration: 
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 A small fraction of this AcetylCoA (k2) will be converted to HmgCoA.  
Conversion of HmgCoA to mevalonate is the rate-limiting step in cholesterol 
synthesis, and is negatively inhibited by cholesterol (negative feedback loop).  When 
neuronal cholesterol (cholN) is below the threshold value, all HmgCoA that is 
synthesized is used to make mevalonate: 
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 When neuronal cholesterol levels are normal, there is relative excess of 
HmgCoA, which can then be used for other metabolic processes or degraded: 
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Lipidomic Reactions & Interactions: 
 Mevalonate is the precursor to cholesterol; the cholesterol synthesis pathway 
actually has 19 steps between mevalonate and cholesterol, however, these steps have 
been considered trivial for the goals of this model and the average production rate for 
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 All cholesterol synthesis occurs in astrocytes.  This cholesterol must then be 
bound to ApoE and transported from astrocytes to neurons, at a rate t1.  Astrocytic 
cholesterol is also degraded at an extremely slow rate (half-life of 5 years): 
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Proteomic Interactions: 
 When neuronal cholesterol is at or above the threshold value, there is no need 
to transport cholesterol to neurons; in this case, the middle term is trivial. The 
concentration of ApoE in astrocytes would also vary similarly (birth minus death 
minus amount transported): 
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 Neuronal cholesterol levels vary depending on the amount of cholesterol being 
transferred from neurons; cholesterol also degrades very slowly (same half-life as 
astrocytic cholesterol): 
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 The ApoE that is used to transport cholesterol from astrocytes to neurons is 
often recycled back to the cell surface and, in combination with ApoE that is 
generated by neurons, can be used to transport Aβ from the brain to the blood in a 
two-step process of Aβ binding to ApoE, followed by transport across the blood-brain 
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When neuronal cholesterol levels are above threshold, there is only trivial amounts of 
cholesterol-laden ApoE being transferred to neurons, and thus, very minimal 
recycling of ApoE back to the surface to be part of the free ApoE pool.  The amount 
of total LRP in the system is assumed to stay at a constant value. 
APP Processing: 
 APP is processed into Aβ via a two-step process by action of beta-secretase, 
followed by cleavage by gamma-secretase.  No difference has been made between the 
40 and 42 amino acid length forms.  Beta-secretase activity is believed to be regulated 
by levels of neuronal cholesterol.  In this model, we have used the evidence presented 
by Crameri et al to introduce an inhibitory effect of cholesterol on beta-secretase 
activity: 
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Beta amyloid is produced from this cleavage, but is also degraded via endocytosis or 
binding and removal by ApoE/LRP-1: 
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Rate constants for generation and degradation of most key molecules were 




Table 6: Values used for Rate Constants.  Rate constants were derived from the 
literature or estimated as a fraction of where the output would go.  All rate constants 
were estimated except for the degradation rate of cholesterol (t1). 
and the strength of inhibition were all approximated and fitted to create a stable 
simulation environment.  All rates have units of x/day
-1
.  Table 6 describes the rate 
constants that were used in the model. 
Simulation Methodology 
 The system of equations was solved numerically using ODE45 solver in 
Matlab.  Initial conditions, rate constants, magnitude and frequency of input, and 
expression levels of different proteins were varied to study their effect on the system 
and more specifically, on the beta amyloid levels (though increased beta amyloid 
levels does not inherently imply that the system has shifted to a disease state, simply 
that the system being modeled is behaving similarly to what is seen in a disease 
model).  The time step for each simulation was a single day.  The model was 
initialized with values that would be found in an average 20 year old and run for a 
total of approximately 55 years (final age 75 years) to correspond to the time period 
Rate Value (day-1) Rate Value (day-1) Rate 
Value (day-1) 
k1 0.9 bn 2000 
t2 0.5 
k2 0.05 ba 750 
kf1 0.005 
k3 0.05 d1 0.8 
kf2 0.001 
k4 1 d2 1/1825 
kf3 0.005 
k5 1 d3 0.8336 
α 0.001 
k6 1 d4 8000 
β 0.01 
k7 0.8 
d5 1 γ 0.8 
a1 0.9 
d6 0.9 endo 0.25 
b1 1 




Figure 16: Reference 
simulation.  Standard simulation 
showing a subtle increase in the 
levels of APP.  Only trivial 
increases in Aβ are noticed. 



























when cognitive changes begin to be apparent in individuals who will have 
Alzheimer‟s disease or dementia in late life. 
Simulation Results 
A simulation using all rate constants as described in Table 6 was run as a 
reference.  Convergence was reached for all simulated molecules within the first 6000 
days of the simulation.  Only APP continued a slowly upward trend during the 
entirety of the simulation, increasing from an initial value of 1000 to a final value of 




Effect of increased APP and Aβ generation 
Several simulations were run to study the effect that increased initial 
concentrations of APP or increased generation of Aβ have on the system as a whole.  
In two cases (increased initial APP concentration and 25% increased Aβ generation 
rate) led to significant increases in the concentration of APP, and subsequently 




Effect of sinusoidal input functions 
Steroids and other molecules derived from cholesterol often have a sinusoidal 
generation rate related to circadian rhythms.  To study the possible effect of 
oscillatory cholesterol input on the system, we varied cholesterol generation by 
introducing a periodic generator function.  The period of the sinusoid was 
approximately one day, while the magnitude of the function was varied from 0 to 1 
(normal range), 0.25 to 1 (assumes a basal generation rate), and 0 to 2 or 4 (assuming 
an increase in the cholesterol production).  Figure 17 displays simulation results. 
Effect of decreased LRP 
LRP-1 levels have been shown to be decreased in individuals with AD.  To 
study this, we varied the LRP levels from 25% to 75% of levels used in the reference 
simulation.  Figure 18 displays these results. 
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Figure 17: Effect of Increased Initial APP concentration or increased Aβ cleavage. (a) 
Initial APP levels were doubled, leading to a significant increase in the amount of APP and 
Aβ present in the system.  HmgCoA levels began to drop slightly as Aβ levels started to 
increase. Final APP level: 2672; final Aβ level: 40 (b) Aβ generation rates were increased by 
25%, leading APP levels to nearly double.  Ironically, Aβ levels did not change significantly.  
Final APP level: 1821; final Aβ level: 27 (c) Aβ generation rates were increased by 12.5%, 
leading APP levels to increase slightly.  Aβ levels did not change significantly.  Final APP 
level: 1345; final Aβ level: 20 





















































































 Effect of decreased Neuronal Cholesterol 

















































































Figure 18: Effect of Periodic Cholesterol Generation.  (a) Sinusoidal generation of cholesterol 
assuming a basal generation rate.  Magnitude of generation rate varies from 0.25 to 1.  k5 = 
0.375*sin(2πt-π/2)+0.625. Final APP: 1349; final Aβ: 20. (b) Magnitude of generation rate varied 
from 0 to 1.  k5 = 0.5sin(2πt-π/2)+0.5. Final APP: 1187; final Aβ: 18. (c) Magnitude of generation 
rate varied from 0 to 2.  k5 = sin(2πt-π/2)+1. Final APP: 1297; final Aβ: 19. (d) Magnitude of 






Recently, a lot of interest has been paid to the effect of cholesterol on APP 
processing and Aβ levels in the brain.  Although treatment with a statin is now being 
studied as a possible treatment paradigm, there are a multitude of conflicting results.  
In these simulations, the effect of decreased neuronal cholesterol on the system was 
studied.  Specifically, the effect of decreased initial cholesterol concentration, as well 
as a decrease in the transfer of cholesterol from astrocytes to neurons, was studied.  





Figure 19: Effect of Decreased LRP: (a) LRP levels decreased by 25%.  Final APP: 1520; 
final Aβ: 23.  (b) LRP levels decreased by 50%.  Final APP: 1431; final Aβ: 22.  (c) LRP 
levels decreased by 75%.  Final APP: 1828; final Aβ: 29.   































































































Effect of increased APP and/or Aβ generation: 
 Increasing the initial concentration of APP led to a significantly increased 
concentration of APP in the long-term (2672 versus 1183), as well as a nearly double 
increase in Aβ (40 versus 18).  This seems to imply that, at least in this model, there 
are few mechanisms keeping the APP levels in check, and if a significant increase in 
APP occurs during the formative years, it may have significant negative 
consequences years later. 
Increasing the generation rate of Aβ by 25% led to a significant increase in the 
amount of APP in the system.  However, the levels of Aβ only increased moderately 

















































































Figure 20: Effect of Decreased 
Neuronal Cholesterol: (a) Initial 
neuronal cholesterol decreased by 
½.  Final APP: 1207; final Aβ: 
18.  (b) Cholesterol transfer rate 
decreased by 50%.  Final APP: 
781; final Aβ: 12.  (c) Cholesterol 
transfer rate decreased by 90%.  







(27 versus 18).  It is a bit unexpected that the APP levels would increase so 
dramatically without an equally significant increase in Aβ levels.  This could be 
explained by the fact that Aβ cleavage is a relatively uncommon event in the first 
place, and that a critical level of APP must be achieved before significant changes in 
Aβ are also observed.  This seems to be a bit counterintuitive and not necessarily in 
agreement with biological data, since APP levels are not significantly increased in 
AD, and increases in Aβ are thought to be due more to decreased clearance rather 
than increased generation.  Further studies on this effect, as well as refinement of the 
model to prevent the increase in APP that is seen over time even in the standard 
reference simulation. 
Effect of sinusoidal input functions: 
 Oscillatory generation of astrocytic cholesterol led to significant changes in 
the system output only in the case where the magnitude of the generation rate 
constant was varied from 0 to 4.  This would correlate to „uncalibrated‟ generation of 
cholesterol by astrocytes.  This increased level of cholesterol in astrocytes led to an 
increase in the amount of APP and a moderate increase in Aβ, which was unexpected 
given the inhibitory regulation that is supposed to exist between cholesterol and APP 
processing by beta-secretase.  Since neuronal cholesterol levels stay approximately 
constant, and it is these levels that effect APP processing, it may be possible that the 
increased APP may be due to other factors that have not been directly studied here.  It 
is also interesting to note that the degradation rate for APP was highly sensitive and 




in itself may provide some insight into why APP levels may respond to such small 
changes in other molecules in the system. 
Effect of Decreased LRP: 
 Decreasing LRP-1 levels led to an increase in APP as well as Aβ.  This was 
the expected result since LRP-1 is necessary to clear Aβ from the brain.  Future 
computational models should further subdivide the LRP into neuronal and endothelial 
to make an even more accurate model. 
Effect of Decreased Neuronal Cholesterol: 
 Decreasing the initial value of neuronal cholesterol did not change the 
outcome of the system for any of the molecules studied.  This was expected, given 
that a strong feedback loop was used to keep neuronal cholesterol within tight 
bounds.  Future simulations should study the effect of this feedback to get a better 
idea of its importance in maintaining the system within the realm of stability.  
Decreasing the rate of transfer of cholesterol from astrocytes to neurons significantly 
decreased the levels of APP and Aβ.  Such a situation might arise if ApoE did not 
carry cholesterol as well, or if fewer LRP receptors were present on neurons.  
However, it is interesting to note that even with a decreased efficiency of transfer, 
neuronal cholesterol levels were maintained at approximately constant levels.  Just as 
in the study of the effects of oscillatory cholesterol production by astrocytes, the 







In this section, we have presented one of the first systems biology models for 
Alzheimer‟s disease.  We have studied in computational detail the interactions 
between cholesterol, ApoE, LRP-1 and Aβ.  Simulation results showed several 
unexpected phenomena, including a decrease in APP and Aβ when the transfer rate of 
cholesterol between astrocytes and neurons is decreased.  These results show that 
cholesterol and LRP levels play significant roles in the development of increased Aβ 
levels in the brain, one of the key markers for AD.  Future models should study these 
effects in further detail and incorporate aspects of inflammation that are believed to 


















Chapter 5:  Biological Experiments 
 
Simvastatin Treatment: 
 C57BLK mice on a mixed background (n= 44, donated by Dr. Mary Ann 
Ottinger), as well as B6C3-Tg(APPswe, PSEN1dE9)85Dbo/J mice (n=13, Jackson 
Laboratories) were used in experiments.  These mice contained a double transgene for 
APP/PS1, which has been shown to lead to plaque development by 6 months of age, 
and cognitive impairments soon after.  An equal number of age-matched controls 
were also obtained.  Mice were treated with 100 mg/kg/day of simvastatin (Fisher 
Scientific) for either 2 or 8 weeks, in addition to normal chow and free-range water.  
Mice were weighed initially to ascertain that the correct dosage per weight was being 
given.  Simvastatin was diluted into 40% Tween-20 to ensure accurate dosage in each 
mouse, and mixed with peanut butter to be more palpable (Giant brand natural peanut 
butter, Greenbelt, MD).  Control mice received peanut butter loaded only with the 
40% Tween-20 daily for the duration of the trial.  The same control animals were 
used for both the 2 week and the 8 week trials.   
Group Treatment (with simvastatin) # in each group 
Control (wild-type) 
mice 
Short (2 weeks) 
No treatment N = 2 for WB 
100 mg/kg 
 N = 10 for WB 
N = 2 for IHC 
Long (8 weeks) 
No treatment 
N = 4 for WB 
N = 2 for IHC 
100 mg/kg 
N = 5 for WB 
N = 2 for IHC 
APPswe;PS1ΔE9 
transgenic mice 
Short (2 weeks) 
No treatment N = 1 for WB 
100 mg/kg 
N = 7 for WB 
N = 2 for IHC 
Long (8 weeks) 
No treatment N = 2 for IHC 
100 mg/kg 
N = 6 for WB 
N = 2 for IHC 
 
Table 7: Treatment table summarizing mice usage in simvastatin trial.  Distribution of mice into 





Measurement of serum 24S-hydroxycholesterol: 
 Blood from terminal mouse bleeds was collected from mice, separated using a 
serum separation tube and stored at -80C until further processing.  To isolate the 
sterol components of the serum, a previously developed protocol was modified.  
Briefly, serum was thawed to room temperature and 50 μL of serum was spiked with 
24S-hydroxycholesterol- d7 internal standard (Avanti Lipids) at a concentration of 4 
ppm.  Samples were saponified for 1 hour at 37°C after addition of 200 l of 0.9 M 
sodium hydroxide (diluted in 90% ethanol in water).  The saponification product was 
diluted into 100 l of aqueous sodium chloride and the organic layer was extracted 
using 700 l of hexane and dried by applying light flow of nitrogen gas.  Prior to 
being running through HPLC, the dried product was dissolved into 10 l of the 
mobile phase (methanol at a 14:1 ratio with deionized water).   
 An AccuTOF-CS ESI-TOF (electrospray ionization time of flight) mass 
spectrometer equipped with an atmospheric pressure chemical ionization (APCI) 
source was used to run HPLC samples. The protocol used here was modified from a 
previously developed protocol for detecting 24S-hydroxycholesterol from plasma 
samples [40].  The ionization interface was operated in the positive mode using the 
following settings: desolving chamber temperature, 350 °C; oriface temperature, 100 
°C; corona discharge current, 4kV; chamber pressure, 49 barr; flow rate, 0.250 
ml/min. The LC-MS system was composed of an in-line auto-sampler and HPLC 
pump.  Oxysterols were separated using a C18 RP-HPLC column. The HPLC column 
temperature was room temperature (25 °C). The mobile phase consisted of 




minute column wash was included. The injection volume was 10 ul in mobile phase.  
A single pole MS system to monitor for specific elution times in reference to the 
standards elution time, as well as m/z of 305, 329, 330, 367, 373/374 and 385.  The 
385 and 367 mass-to-charge ratios were barely detectable in the majority of samples, 
so are not included in the final data set that was analyzed. 
Measurement of total serum cholesterol: 
 Blood from mice (50-100 μL/mouse) was taken prior to initiation of treatment 
via saphenous vein bleeding.  Initially, bi-weekly bleeding was done for several mice, 
though bleeding was stopped when a few mice (n=2) became infected and ill.  
Terminal blood was collected immediately after sacrifice to determine the value of 
the final cholesterol concentration.  Blood was collected into serum separator tubes 
(Becton Dickinson, Franklin Lakes, NJ, US) to separate serum from red blood cells, 
and spun on a table-top centrifuge kept at 4⁰C for 10 minutes at 4000 rpm.  Samples 
were then stored at -80⁰C until further usage.   
Serum cholesterol levels were measured using the Amplex Red Cholesterol 
Assay (Invitrogen, CA).  Briefly, standard cholesterol solutions were prepared using 
the supplied cholesterol stock solution and used to create a standard curve (Range: 0-
25 μg/μL).  Sample serum was diluted 1:100 in reaction buffer and mixed with the 
Amplex Red solution, before being incubated for 30 minutes in a hot water bath kept 
at 37⁰C.  Detergents in the reaction buffer (Triton-X) prevented the formation of large 
aggregates of lipid-soluble molecules.  Following incubation, fluorescence intensity 




(Molecular Devices SpectraMax5 microplate reader, Sunnyvale, CA, US; 
excitation/emission: 540/580 nm).  
Western Blotting: 
Western blotting was performed using standard procedures to assay for the 
approximate expression levels of several proteins of interest: synaptophysin (Sy38, 
pre-synaptic marker); post-synaptic density 95 (PSD95, post-synaptic marker, used 
with Sy38 to quantify if changes in synaptic density occur); apolipoprotein E (ApoE); 
glial fibrillary acidic protein (GFAP, astrocytic and inflammatory level marker); low 
density lipoprotein receptor-related protein (LRP-1); amyloid precursor protein 
(APP) and beta amyloid (A).  These levels were assessed to study how they changed 
during simvastatin treatment, as well as to gather key data for development of more 
realistic concentration ratios and constants used in the systems biology math model. 
Samples were prepared using the following protocol.  Briefly, six hours 
following the final treatment, mice were sedated using isoflurane and sacrificed via 
decapitation.  Immediately following sacrifice and terminal bleeding, brains were 
excised and the hippocampus was isolated.  Both the hippocampus and the whole 
brain (minus the cerebellum and meninges) were transferred to a pre-chilled 
centrifuge tube and frozen at -80⁰C until further usage.   
To prepare samples for Western blotting, brain tissue was thawed to room 
temperature and 500 μL of ice-sold lysis buffer containing 10 U/ml protease inhibitor 
was added (Sigma).  Samples were then sonicated to homogenize tissue, followed by 
centrifugation at 1,000 rpm for 10 minutes at 4⁰C to remove unhomogenized tissue.  




μL of Coomassie reagent and measuring the absorbance at 595 nm.  Bovine serum 
albumin protein standards (0-2 mg/ml) were also assayed to calculate the approximate 
protein concentration in samples.  Samples were then mixed with 1x GSB and 
normalized to 1-3 mg/ml of protein. 
 Several different gels were used to run the Western, depending on which 
protein was being assayed.  Higher molecular weight proteins (APP, LRP) were run 
on 6% gels, lower molecular weight proteins (Sy38, PSD 95, ApoE, GFAP) were run 
on 10% gels, and beta amyloid Westerns were run on 4-20% gradient gels (Bio-Rad, 
Hercules, CA).  All gels were run in triplicate using one of three loading schema to 
account for possible variations in running or transfer conditions due to 
instrumentation or other factors associated with the gel boxes.   
Twenty micrograms of protein was loaded into each sample lane (30 μg for 
Aβ gels); a standard ladder was also loaded onto each gel (ECL-Plex ladder, GE 
Healthcare, Piscataway, NJ, US) and the appropriate standard for each protein.  Beta 
amyloid gels were run at 100 V for 40 minutes in MES buffer (2-
[morpholino]ethanesulfonic acid buffer, 20x, Fisher Scientific, Pittsburgh, PA, US).  
Samples were specially prepared to contain 100 mM DTT (dithiothreitol) as a 
reducing agent (1.54 μl of 1 mg/ml stock DTT into 100 μl of sample).  Blots were 
transferred using standard transfer buffer (3 g Tris base, 14.4 g glycine, diluted into 
1600 ml ddH2O, brought up to 2 L with methanol) at room temperature kept under 
ice for 60 minutes.  All other gels were run at 100 V for 75 minutes using standard 
running buffer (25 mM Tris base, 250 mM glycine, 0.1 % w/v SDS, pH 8.3) and 




cases, gels were transferred to nitrocellulose membranes that had been pre-wet in 
methanol.   
Following transfer, blots were incubated in blocking solution (1% bovine 
serum albumin, 0.1% Tween-20 into 1x phosphate buffer solution) for 1 hour at room 
temperature, agitated gently on a shaker.  Blots were then incubated in primary 
antibody overnight on a shaker at 4˚C.  After primary incubation, blots were rinsed 3 
times for 5 minutes each in blocking solution, incubated for 1.5 hours in the 
appropriate secondary antibody (mouse Cy3/Cy5, rabbit Cy3/Cy5, AlexaFluor 555 
goat-anti-chicken secondary, or AlexaFluor 633 donkey-anti-goat secondary) and 
rinsed 3 additional times for 5 minutes each in blocking solution before being imaged 
with a blot scanner (Typhoon Scanner, GE Healthcare, Piscataway, NJ, US).  The 
following table describes in further detail the primary and corresponding secondary 
antibodies that were used. 
Analysis of Western Blot Data 
Data was analyzed using ImageQuant software (GE Healthcare, Piscataway, 
NJ, US).  Briefly, scanned gel images were loaded into the software program, lanes 
were manually created, the background was thresholded to remove noise, and the 
intensity of the band in each lane was measured.  Values were tabulated and saved in 
an Excel file for further statistical analysis. 
Immunohistochemistry 
 Immunohistochemistry was performed to determine the cellular localization of 
ApoE in astrocytes in response to simvastatin treatment; the relative density of LRP-1 




load.  All protocols described below were approved by the University of Maryland 
IACUC committee (protocol #R10-21, renewed March 2011).  Briefly, mice were 
anesthetized using isoflurane, the thoracic cavity was accessed and 20 ml pre-warmed 
PBS was injected into the left ventricle following puncture of the right atrium to clear 
blood from the vessels and allow for a better perfusion.  Terminal blood was collected 
in serum separator tubes prior to pumping of the pre-warmed PBS and stored as 






















Santa Cruz Biotech, 
M-293) 
























1:1000 RCy5 1:2500 
Aβ 6E10 (Covance) 1:1000 MCy5 1:2500 
 
After completion of injection of PBS, mice were fixed with 4% 
paraformaldehyde (PFA; Fisher Scientific), decapitated and the brain was removed.  
The cerebellum was removed and the remaining portions of the brain were placed 
into 4% PFA overnight to ensure complete fixation.  Brains were then sunk in 30% 
sucrose (diluted in 0.1 M phosphate buffer) overnight at 4˚C.  The following day, 
brains were rinsed in 30% sucrose, extraneous material was removed, and the brain 




was mounted on a freezing microtome with a sucrose stand.  Twenty µm slices were 
obtained and stored in cryoprotectant at -20˚C until further usage. 
On the day of primary incubation, 20 slices from each treatment group (10 
slices per mouse; n =2 for each immunohistochemistry group) were thawed at room 
temperature briefly before being rinsed 4 times for 5 minutes each in 1x PBS at room 
temperature.  Sections were then permeabilized by incubating in 2% Triton-X in 
sodium phosphate buffer for 1 hour at room temperature.  Following 
permeabilization, slices were incubated in ice cold methanol for 10 minutes to quench 
background signal.  Slices were then rinsed again 4 times for 5 minutes each in 1x 
PBS on a gentle rotator and incubated for 1 hour in blocking solution (10% normal 
donkey serum, 1% Triton-X, 4% BSA in 1x PBS) at room temperature.  Finally, 
sections were incubated in primary antibody overnight, either at room temperature or 
at 4˚C.  All primary antibodies were diluted into the same blocking solution 
consisting of 1.5 ml normal donkey serum, 0.5 ml 20% Triton-X, and 6 ml of 10% 
BSA into 7.35 ml of 1x PBS.  
Following primary incubation, slices were rinsed 4 times for 5 minutes each in 
1x PBS to remove excess primary antibody, incubated in the appropriate secondary 
antibody in blocking solution (1.5% normal donkey serum in 1x PBS) for 2 hours at 
room temperature on a gentle rocker, protected from light, and rinsed again after 
incubation (4x for 5 minutes each time).  Slices were incubated for ten additional 
minutes prior to being mounted on superfrost slides (Fisher Scientific, Pittsburgh, PA; 
pre-cleaned with 70% ethanol) and air-dried overnight protected from light.  DAPI 




minutes prior to the secondary antibody incubation ending.  The next day, slices were 
cover-slipped with mounting solution (ProLong Gold Anti-fade mounting solution, 
Invitrogen), excess mounting solution was removed with Kimwipes, and allowed to 
dry overnight. Cover-slipped slides were sealed with clear nail polish.  The following 
tables describe in further detail the antibodies that were used for each set of slices and 





















Donkey anti-rabbit 488 
Goat anti-chicken 555 




Label LRP-1 levels 










Donkey anti-goat 633 
Donkey anti-rabbit 488 












(DAPI for 10 
minutes) 
Donkey anti-mouse 450 1:200 
 
 
Imaging Acquisition & Analysis 
 Immunohistochemistry sections (n= 360, ~120 per group) were imaged using 
a Zeiss LSM confocal microscope (Zeiss, Germany).  ApoE and LRP sections were 
imaged with a 40x oil objective, while Aβ sections were imaged with a 10x objective.  
The CA1 region of the hippocampus was identified with the visual view and 



























Table 9: (Top) Details on dilution and incubation conditions used for immuno-histochemistry.  




subsequently imaged.  Images were taken with Zeiss software program, at 1024 x 
1024 bits set at speed 6 to optimize the resolution of the image.  Overall image area 
was 212.3 x 212.3 µm.  pixel size was set to 0.21 µm.  Images quantifying the levels 
of LRP used the 405, 488 and 633 lasers at the following settings: 405: laser power 
was set to 4.0, pinhole was 47.6, gain was 626, offset was -7 and digital gain was 1.1; 
488:  laser power was set to 1.8, pinhole was 47.6, gain was 790, offset was -1 and 
digital gain was 1.2; 633: laser power was set to 15.0, pinhole was 47.6, gain was 
727, offset was -8 and digital gain was 1.0.  For GFAP images, laser settings were as 
follows: 405: laser power was set to 4.0, pinhole was 57.7, gain was 556, offset was -
7 and digital gain was 1.3; 488:  laser power was set to 1.8, pinhole was 57.7, gain 
was 597, offset was -8 and digital gain was 1.3; 555: laser power was set to 1.5, 
pinhole was 57.7, gain was 431, offset was -5 and digital gain was 1.2.  For beta 
amyloid images, only the 405 and 633 lasers were used: 405: laser power was set to 
4.0, pinhole was 47.6, gain was 735, offset was -6 and digital gain was 1.1; 633: laser 
power was set to 15.0, pinhole was 47.6, gain was 660, offset was -7 and digital gain 
was 1.0. 
 Images were analyzed using the software program Volocity (PerkinElmer, 
Waltham, MA, US).  For ApoE and LRP slices, image stacks were loaded into 
Volocity, images were split into their corresponding z stacks by channel, and the four 
images with the highest signal intensity for ApoE and LRP were selected and re-
merged.  A protocol was then created to identify all regions of that image where 
astrocytes (stained by GFAP; red channel) and cerebral blood vessels (stained by 




channel within the identified region (red and green channels for both ApoE and LRP 
sections), and the sum of this intensity was calculated for each image.  The total 
volume of the image was also calculated and used to determine the overlapping 
intensities between the two channels per volume (effective “co-localization” density). 
Cholesterol & 24S-hydroxycholesterol levels in plasma 
Data from the cholesterol assay was tabulated and analyzed using Excel.  
Cholesterol values derived from brain samples were normalized against the µg of 
protein in the sample, while plasma samples were simply measured in µg/ml of 
plasma.  A standard control curve was obtained and all sample fluorescence values 
were normalized to this curve and the concentration adjusted to account for 
differences in dilution. 
 Data from the brain cholesterol assay was analyzed using Excel.  Normality of 
data sets was assessed using the histogram function.  Bar graphs were used to 
visualize data.  Brain cholesterol levels were analyzed using a single factor ANOVA 
for each genotype of mice.  There was no statistically significant difference in the 
brain cholesterol levels for APP mice, regardless of treatment regime.  Conversely, 
WT mice had statistically significant differences at 90% confidence levels (F=3.013, 
p-value = 0.072).  This was further verified by t-tests, which showed that the 
differences between both the 2 week treatment and 8 week treatment groups were 
statistically significant at 90% confidence (for 2 week: t = 1.82, p-value<0.056; for 8 
week: t= 1.48, p-value<0.087).  This seems to suggest that treatment with simvastatin 




levels of brain cholesterol in WT mice.  An increased sample size in future 




A single factor ANOVA done on wild-type and transgenic groups separately 
demonstrated that both pre-treatment groups had no statistical difference between the 
mean values across any treatment group (for WT: F = 0.435, p-value = 0.655; for 



























Variation of Brain Cholesterol 
WT
APP
Figure 21: Variation of Brain Cholesterol Levels. Cholesterol assay data was visualized 
using histograms to check whether or not the data was normal and could be analyzed 
using ANOVA and other parametric tests.  Only wild-type mice treated with simvastatin 
for 2 or 8 weeks showed a statistically significant decrease in brain cholesterol levels (for 
2 week: t = 1.82, p-value<0.056; for 8 week: t= 1.48, p-value<0.087).  No statistically 
significant variation was observed in APP transgenic mice.  Simvastatin treatment 
appears to decrease the overall variability in the brain cholesterol level across both wild-
type and transgenic mice.  Long-term treatment with simvastatin does not appear to lead 




approximately the same level of total plasma cholesterol.   Single-factor ANOVA on 
post-treatment WT and APP groups demonstrated that means across the three 
treatment groups varied with 95% and 90% confidence, respectively (for WT: F = 
6.53, p-value = 0.009; for APP: F= 3.307, p-value = .057).   Further analysis with t-
tests showed that only the 2 week APP treatment group was statistically different 
from the control APP group (t=2.609, one-tail P-value=0.0114, 95% significance).  
All other control versus treatment group t-tests showed no statistical significance; the 
control versus 2 week WT treatment group was statistically significant at 90% 
significance (t=1.898, P-value=0.0532) but not at 95% significance.  One reason for 
the statistical indifference in our data set is the small sample size that was used.  
Increasing the sample size will help to minimize the variation and is suggested for 
future experiments.   
The differences between the mean pre- and post-treatment values were also 
analyzed using ANOVA and t-tests.  In this case, differences in means across the APP 
transgenic group were statistically significant (F= 5.177, p-value < 0.022), whereas 
differences across the WT groups were not (F=2.34, p-value <0.167).  Only the 2 
week APP treatment group showed statistical significance in differences in mean pre- 
and post-treatment plasma TC values (t = 3.522, p-value <0.012), suggesting that 
treatment with simvastatin for 2 weeks in transgenic mice was able to prevent the 
observed increase in plasma total cholesterol (TC).  All other groups were statistically 
insignificant.  Although a similar trend is observed in the WT data set in terms of a 
decreased mean post-treatment TC at 2 weeks, due to the relatively large variability in 
















































Control WT 2 wk WT 8 wk WT Control
APP


















Pre- vs Post- Treatment Total Plasma Cholesterol 
Pre
Post
Figure 22: Differences between Pre- and Post-Treatment Plasma Cholesterol. Plasma 
cholesterol levels (mg/dl) were measured at an initial time point before treatment was 
started, and then again terminally to study how cholesterol levels changed over the course 
of treatment.  In all groups studied, the cholesterol levels increased between the initial 
and the final measured time points.  This could be due to the high fat content of peanut 
butter.  Although there is an increase in plasma cholesterol in all groups, the magnitude 
of this difference in statistically significant in the APP transgenic mice (F = 5.176, p-
value = 0.022, α = 0.05), and more specifically, this difference exists between the control 




 Correlation between total plasma cholesterol and total brain cholesterol levels, 
as well as between total plasma cholesterol levels and age of the mice during 
treatment was investigated.  No significant correlation existed between pre- and post-
treatment plasma cholesterol levels (linear regression, R
2
 = 0.1784).  Plotting total 
plasma cholesterol versus total brain cholesterol for all samples that could be matched 
revealed only a very weak positive correlation between total plasma cholesterol levels 
and total brain cholesterol levels (R
2
 = 0.2002), indicating that increased plasma total 
cholesterol levels were associated with a minor increase in brain total cholesterol 





































Plasma Total Cholesterol 
Correlation between Plasma TC and Brain 
TC 
Figure 23: Correlation 
between Plasma 
Cholesterol and Brain 
Cholesterol Levels. (top 
inset) Pre- and post-
treatment total plasma 
cholesterol levels were 
plotted to determine if any 
correlation existed between 
the pre- and post- treatment 
values.  A weak positive 
correlation was found (R
2
 = 
0.1784), suggesting that 
higher values of pre-
treatment cholesterol led to 
a more significant increase 
in post-treatment cholesterol 
levels.  (bottom inset) 
Correlation between post-
treatment plasma cholesterol 
levels and brain cholesterol 




0.2002), suggesting that 
increased plasma cholesterol 
levels may affect brain 
cholesterol levels.  
However, removing the few 
data points that appear to be 
outliers (n=2), this 
correlation all but 
disappears and is therefore 
more an artifact of relatively 


















Correlation between Pre- and Post-Treatment 










 Correlation analysis was also completed by separating the data by treatment 
group (WT and APP grouped together).  It can be seen that the majority of the 2 week 
treatment group is clustered in the lower left corner, indicating that the data has the 
least variation of the three treatment groups, as well as a limited range of values.  In 
this sense, treatment of either WT or transgenic mice with simvastatin seemed to 
normalize the effect between plasma cholesterol and brain cholesterol.  Analogously, 
the 8 week treatment group had a wide range for possible plasma total cholesterol 
values, but a very limited range on the corresponding brain cholesterol values, 
demonstrating that simvastatin treatment provides a normalizing or convergent effect 
on brain cholesterol levels.  Although the means in total brain cholesterol were not 
statistically different between the treatment groups for either the WT or the APP 
transgenic groups, the variability between measurements was decreased. Correlation 
data showed weak positive correlation: control:  R
2
 = 0.2848; 2 week treat: R
2
 = 
0.248; 8 week treat: R
2
 = 0.3631.  In the future, a larger sample size would help to 
possibly eliminate some of the variability that is seen here, as well as in other data 
sets.  The regression data also seems to suggest that as plasma cholesterol increases, 
total brain cholesterol increases mildly, though more sample data is needed to draw 
such a statistical conclusion. 
 Lastly, age versus cholesterol levels was studied.  To determine whether the 
observed increase in post-treatment plasma cholesterol in the control and 8 week 
treatment groups was due to increasing age, a scatter plot of the data was done for 
both pre- and post-treatment cholesterol as a function of age, as well as scatter plots 




linear  correlation between age and total plasma cholesterol levels in either the pre- or 
post-treatment groups (for pre: R
2
 = 0.0113, negative correlation; for post: R
2
 = 
0.0012, positive correlation), suggesting that plasma TC levels are independent of 
mouse age.  This independence of age from plasma TC is most apparent in the pre-
treatment group, where mice of the same age at starting have significant variability in 
their plasma TC levels (41 weeks in the pre-treatment scatter plot is a good example 
of this).  This variability in plasma TC levels also appears to be independent of 
genotype.  Looking at the post-treatment TC by treatment group, the correlation 
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Figure 24: Correlation between Plasma and Brain Total Cholesterol. Brain cholesterol 
levels (mg/dl) were plotted as a function of post-treatment total plasma cholesterol levels.  
Very weak correlation was found between plasma cholesterol and brain cholesterol levels 
(control:  R
2
 = 0.2848; 2 week treat: R
2
 = 0.248; 8 week treat: R
2
 = 0.3631), which, 
upon removal of outliers, disappeared.  This suggests that the correlation seen here 
between plasma cholesterol levels and brain cholesterol levels is quite weak and would 
need a larger sample size to verify its accuracy.  The data here do show though that 
treatment of mice with simvastatin appears to decrease the variability in the brain 





APP have mild negative correlations (R
2
 = 0.054, 0.0086 and 0.1664, respectively), 
while control APP, 2 week WT, and 8 week WT have positive correlations (R
2
 = 
0.3706, 0.1499, and 0.3784, respectively).  The only statistically relevant correlations 
are control APP and 8 week WT.  This implies, like the net data analyzed above, that 
there is no distinct correlation between age of the mouse and level of brain total 
cholesterol. 
     Other confounding factors may also have been at play.  For example, there were 
some issues with the 8 week treatment mice that they adjusted to the peanut butter 
with drug and refused to eat duped peanut butter samples.  Although this was 
overcome by dosing the mice briefly with drug in baby food, this may have had an 
unexpected effect on our outcomes for this group.  The increase in cholesterol may 
have been due to an age-dependent effect, as has been suggested; however, there is 
not statistically relevant data in this sample to make that conclusion.  Another factor 
that may have been at play is the fact that peanut butter, due to its high fat content, is 
expected to increase cholesterol over long term treatment.  Within the shorter time 
periods, this increase in fat in the mouse‟s diet should not have had an effect on the 
plasma cholesterol values.  The exact time point when this mild increase in fat to the 
mice‟s diet would lead to increased cholesterol levels has not been investigated for 
the mice that were used here.  Also, although mice were age-matched for final time 
points, the initial blood draw occurred immediately before the group was started on 
treatment (either 2 or 8 weeks before treatment finished).  This may have led to 
different rates of changes in the plasma cholesterol depending on the age of the 




APP) that were treated as control (peanut butter plus Tween-20 only) for 2 week 
periods of time.  These samples show a normal pre-treatment value for TC, with a 
qualitative increase in final TC levels equal to or greater than mice that had been on 
treatment for the entire 8 week period.  Finally, the increased cholesterol in the 8 
week treatment group may have been caused by a „rebounding‟ effect often seen in 
human subjects treated with statins longer than 12 months [50].  Previous studies 
have also shown that a similar simvastatin dosage does not actually lead to decreased 
plasma cholesterol, and in apoE null mice, actually leads to an increase in plasma 
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Figure 25: Average Cholesterol as a Function of Age. Brain cholesterol levels (mg/dl) 
were plotted as a function of the age of mice before and after treatment.  No correlation 
was found between age and total post-treatment plasma cholesterol levels (for pre: R
2
 = 
0.0113, negative correlation; for post: R
2
 = 0.0012, positive correlation), suggesting that 
plasma cholesterol levels are independent of age and that the observed increases in 
plasma cholesterol seen in mice are due to treatment with peanut butter, as opposed to an 
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Figure 26: Average Cholesterol as a Function of Age. Brain cholesterol levels (mg/dl) 
were plotted as a function of the age of mice before and after treatment on separate plots.  
No correlation was found between age and total pre-treatment plasma cholesterol levels. 
Weak correlations were seen in two groups in the post-treatment plot: control APP (R
2
 = 
0.3706) and 8 week WT (R
2
 = 0.3784), while no correlation was seen in other groups 
(both positive and negative correlations were seen).   This suggests that plasma 




Western Blot Results & Quantification 
 Western blots were used to assess protein levels semi-quantitatively to 
determine whether statistically significant changes or relevant trends were apparent in 
the data following treatment with simvastatin.  Of particular interest was how ApoE, 
LRP and Aβ changed in response to simvastatin so results could be compared to the 
immunohistochemistry results.  Although n=15 blots per group were performed (more 
blots were run in many cases), many groups did not have more than 12 blots with 
usable data, thus sample size was somewhat lacking.  However, trends in the data 
could still be seen, as discussed further here, though they are not statistically 
significant. 
APP & Aβ Results: 
 Western blot results for APP and beta amyloid are shown in the following 
figure.  No statistically significant level of beta amyloid expression was observed 
between treatment group (p< 0.288; two-way ANOVA).  There was also no 
interaction between genotype or treatment group (p<0.118).  There was a noticeably 
increased expression of beta amyloid by the transgenic group as compared to the 
wild-type group, however, this difference was not statistically significant (p<0.123). 
It is also important to note that there were three main bands that were observed on the 
beta amyloid westerns: a large band at ~100 kDa representing APP, a medium-sized 
band at ~52 kDa representing C-terminal fragments that had been cleaved from APP, 
and a small band at ~31 kDa representing oligomeric beta amyloid.  Monomeric or 
small oligomeric beta amyloid was not detected in samples, though the Aβ42 




non-detectable levels of oligomeric beta amyloid were present in this sample (<10 
µg/lane).   
Within the APP western blots, a similar trend with no statistical significance 
between genotype or treatment was observed.  There was a decreasing trend in the 
level of APP expression in the transgenic group treated with simvastatin, though the 
change was only very minor (p<0.063 and 0.399, respectively, for between genotype 
and between treatment groups; two-way ANOVA). 
ApoE, GFAP & LRP Results: 
 Again, there were no statistically significant differences between genotype or 
treatment group in the ApoE, GFAP and LRP Western blotting groups.  Within the 
ApoE group, two-way ANOVA analysis revealed relatively high p-values for 
differences in genotype and treatment (p<0.368 and 0.412, respectively).  Within the 
Figure 27: Western Blot Results for APP & Aβ: Western blots for APP and beta 
amyloid showed no statistically significant changes in expression levels of either 
protein.  There was a decreasing trend for APP expression amongst the treated 




GFAP and LRP groups, p-values were also quite high (p<0.7 and 0.45, respectively, 
and 0.84 and 0.62, respectively for LRP). 
Sy38 & PSD95 Results: 
 Post-synaptic density 95 (PSD95) showed the only statistically significant 
difference (p<0.029), suggesting that APP mice had a significant increase in PSD95 
expression when compared to WT mice.  This is an interesting result because AD is 
Figure 28: Western Blot results for ApoE, GFAP & LRP:  Western blots for ApoE, 
GFAP and LRP showed no statistically significant changes in expression levels of either 
protein.  There was a weak increasing trend in the LRP levels in the 2 week treatment 





usually associated with a decrease in synaptic density; a similar trend is also seen in 
the Sy38 expression in the control group.  PSD95 levels appear to have a decreasing 
trend with respect to treatment time, though this decrease is not significant (p<0.845).  
Ironically, WT mice show an increase in PSD95 expression in response to simvastatin 
treatment, suggesting that simvastatin may potentially affect transgenic mice 
differently than wild-type mice. Synaptophysin expression also appeared to have a 
decreasing trend between control and 2 week treatment groups in APP transgenics, 
suggesting that treatment with simvastatin may inhibit the maintenance of synapses, 
however, this difference was not statistically significant (p<0.55  and 0.19, 
respectively between genotype and treatment group, two-way ANOVA).  This was 
the expected result since cholesterol is absolutely necessary for forming and 
maintaining synapses, and treatment with simvastatin would be expected to decrease 
cholesterol levels and subsequently decrease the synaptic density. 
Figure 29: Sy38 & PSD95 Expression Levels: Expression levels of Sy38 and PSD95 had 
a decreasing trend in the APP transgenic group, though no trend was observed in the WT 




Immunohistochemistry Results & Quantification 
Beta Amyloid Results: 
 Beta amyloid levels in the brain were measured semi-quantitatively by 
immunohistochemistry to study the density of plaques, as well as the localization of 
these plaques.  Stained Aβ was divided up into two groups depending on the size of 
the stained region: large plaques (area > 5 µm
3
) and small Aβ plaques (area < 5 µm
3
).  
A plot of this data shows that mice treated with simvastatin, regardless of whether 
they are WT or APP transgenic, have an increased number of beta amyloid plaques.   
Statistical analysis was performed using single factor ANOVA for both wild-
type and APP transgenic mice, which showed that treatment of both WT and 
transgenic mice with simvastatin led to a statistical difference between the means of 
these groups (for WT: F=12.60115, p-value<0.0000323; for APP: F=14.01905, p-
value<0.00000978).   Analyzing further with t-tests revealed that a statistically 
significant difference between control WT and control transgenic mice exists 
(t=5.805, p-value<0.000055), whereas no statistical difference exists between the 2 
week treatment or 8 week treatment groups (p-value<0.163 and 0.090, respectively).  
A statistical difference between the means of the control-treated mice and the 2 and 8 
week-treated mice also exists (for WT: p-value<0.00038 and 0.0029, respectively; for 
APP: p-value<0.028 and 0.000012, respectively).  This seems to further suggest that 
treatment with simvastatin leads to an increase in the Aβ plaque density, regardless of 
whether the mouse is WT or APP transgenic.  This is an interesting outcome which 
seems to suggest that treatment with simvastatin may actually lead to increased 
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Figure 30: Aβ Plaque Density in Mice across Different Treatments.  Beta amyloid plaque 
densities were assayed using immunohistochemistry (IHC).  Dual staining was used to detect 
Aβ (6E10, magenta channel) and neurons (DAPI, blue channel).  Increased levels of Aβ were 
seen in groups treated with simvastatin when compared to controls.  Plaques were not 





Figure 31: Plaque Density in Mice across Different Treatments.  Beta amyloid 
plaque densities were measured for in control, 2 week and 8 week treatment with 
simvastatin.  Treatment with simvastatin, regardless of group type (WT or APP) led 
to an increased plaque density. 
Additionally, this suggests that decreasing cholesterol levels may lead to an increase 
in Aβ expression, a relationship that has been suggested by others in the literature and 






























































Correlation analysis was completed to determine whether plaque density was 
dependent on the age of the mouse.  All mice used for immunohistochemistry were 
greater than 6 months of age, which is the time when beta amyloid plaques have been 
shown to develop at an easily measurable level.  Plaque levels were expected increase 
with age.  Grouping both WT and APP transgenic mice into the same plot showed a 
weak positive correlation between age in plaque density (R
2
 = 0.0764).  Separating 
these out by group type showed a very weak negative correlation with age between 
the APP group (R
2
 = 0.0019), while the WT group showed a weak positive 
correlation (R
2
 = 0.2219). 
Although there appears to be a no measurable correlation between age and 
plaque density, looking at the 6 possible data pairs of old mouse and young mouse for 
each treatment group, we see that in 4 of these 6 pairs, the older mouse has increased 
plaque density (the exceptions being the control WT and 2 week APP groups).  This 
relative lack of correlation may be due again to the relatively small sample size that 
was used (n=2 for each group), which is quite small and can lead to skewed results. 
It is also interesting that the WT mice that were treated with simvastatin 
showed increased Aβ plaque densities.  These seems to suggest that treatment of mice 
with simvastatin, which significantly reduces plasma cholesterol in the 2 week 
treatment group, may have a negative effect on APP processing, leading to increased 
generation of the amyloidogenic processing pathway.  There are several papers in the 
literature which describe a similar trend as well [1, 33], and points towards the role of 
cholesterol as an important modulator in APP processing.  Recent research has also 




beta amyloid, thus leading to increased Aβ levels [144].  This also agrees with 
epidemiological studies that have shown that individuals with AD have decreased 
brain cholesterol, particularly in regions most affected by the disease [86].  Given the 
small sample size, however, it is not fair to put much backing in this result without 
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Figure 32: Correlation between Mouse Age & Plaque Density: No correlation was 
apparent between age and plaque density, suggesting that changes in plaque density 




Figure 33: Average ApoE Intensity of Overlap with Astrocytes in Mice across 
Different Treatments.  Average intensity of ApoE overlap on astrocytes was 
measured in control mice, and in mice treated for 2 and 8 week with simvastatin.  
Intensities were normalized to the total area of astrocytes in each image.  Treatment 
with simvastatin for 2 weeks increased the average intensity of ApoE on astrocytes, 
while 8 week treatment significantly decreased the average intensity of ApoE, 
irrespective of genotype. 
Co-localization of ApoE with astrocytes: 
 The average density of ApoE „co-localizing‟ with astrocytes was studied to 
determine if treatment with simvastatin altered expression levels of this key protein.  
The overlapping intensities between the red (astrocyte) and green (ApoE) channels 
was measured for each image in the set (n=15-20 per treatment group) and plotted in 
a bar graph.  Data showed an increase in ApoE on astrocytes in the 2 week treatment 
group for both WT and APP transgenics, but a significant decrease in ApoE on the 8 

































A single factor ANOVA was done separately for the WT and APP transgenic 
mice to study the statistical difference between the means of treatment groups in these 
samples.  In WT mice, the means between control, 2 week treat, and 8 week treat 
were statistically difference (F=9.49, p-value<0.00031); in APP transgenics, the 
means between these three groups were also statistically significant (F=28.61, p-
value<5.58e-9).  It is important to note that there was considerable variability within 
each group, which can be seen by the relatively wide confidence intervals for each 
group/ relatively large standard deviations.  This could be due to minor changes in the 
laser power at different imaging times, or relative differences in staining that are 
possible even for slices that are placed into the same well (due to folding, not exactly 
the same thicknesses, or relative placement within the well during primary 
incubation).  Still, however, this data suggests that statistically different changes in 
the average intensities were obtained. 
To further study these changes, t tests were performed between matched 
groups.  No statistical difference between WT and APP controls, 2 week, or 8 week 
treated mice was observed for a two-tailed test (for control: t = 0.042, p-value<0.97; 
for 2 week treat: t = 0.995, p-value<0.327; for 8 week: t = 0.11, p-value<0.915).  
Amongst WT mice, a statistical difference was observed between control and 2 week 
treatment, and control and 8 week treatment (p-values<0.028 and 0.014, respectively, 
one-tailed test).  A similar trend was observed in APP transgenic mice where there 
was a significant increase in ApoE in the 2 week treatment group, and a significant 
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Figure 34: GFAP IHC: Hippocampal slices were triple-labeled with GFAP (red channel; glial 
fibrillary acidic protein; labels astrocytes), ApoE (green channel; labels apolipoprotein E) and NeuN 






 The average number of astrocytes in each image was also measured to verify 
that the observed changes in ApoE were not due to changes in the number of 
astrocytes.  The mean astrocyte number in across all groups ranged from 20 to 25 
astrocytes per image.  A single factor ANOVA for WT and APP groups, done 
separately, indicated that there was no statistical difference between these mean 
values (for WT: F=1.12, p-value < 0.3335; for APP: F=0.803, p-value<0.453).  T 
tests done between control/2 week and control/8 week treat for both WT and APP 
samples showed no statistical difference between the mean astrocyte number per 
image (for WT: p-values<0.368 and 0.588; for APP: p-values<0.316 and 0.732, 
respectively; two-tailed test).  This suggests that the observed differences in ApoE are 
more likely due to changes in protein expression rather than changes in astrocyte 
number. 
 Combining the result in this section for ApoE with the cholesterol assay 
results, it is reasonable to suggest that decreasing the plasma cholesterol levels leads 
to a decrease in the observed ApoE expression on astrocytes.  This, in fact, agrees 
with some of the data in the literature (Liu 2007).  The 8 week treatment results are a 
little bit more difficult to interpret, since cholesterol levels were at similar levels to 
the control treated group in both WT and APP mice.  Since ApoE expression is 
increased when cholesterol levels are low and/or when IL-1 levels are high, the 
converse being true also, it is reasonable to suggest that cholesterol levels may have 
been sufficient enough, but inflammation low enough, to prevent an increase in ApoE 
expression.  This would imply that the 8 week treatment of mice with simvastatin has 




Figure 35: Average Astrocyte Density: Average astrocyte density did not vary 
significantly across genotype or treatment group, ranging from 20-25 astrocytes per 
image field. 
inflammation, and thus decrease the expression level of ApoE.  However, the 
astrocytes in the 8 week treated groups do appear to be reactive state rather than in the 
resting state, suggesting that inflammation is actually not decreased.  Further 
experiments measuring the level of inflammation by ELISA or Western blot analysis 
of IL-1 and TNFα would be needed to better determine whether inflammation is 
increased or decreased in treated mice. 
 
 
Co-localization of LRP on cerebral blood vessels & neurons: 
 
 The final set of immunohistochemistry experiments that was done studied the 
expression levels of LRP on both cerebral blood vessels and on neurons to determine 
whether these levels changed individually, and whether the ratio of LRP on cerebral 























data for LRP on cerebral blood vessels showed an increase in LRP in 2 week treated 
WT and a mild increase in 2 week treat APP mice.  Little change between the control 
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Figure 36: LRP IHC: Hippocampal slices were triple-labeled with LRP (red channel; labels LRP 




Figure 37: Average LRP Intensity on Cerebral Blood Vessels: Average LRP intensity 
on cerebral blood vessel was increased significantly only in the 2 week and 8 week WT 
groups (*), although all treatment groups showed an increase with respect to the control 
group.  There was no significant increase in either treatment group for APP mice.  The 
difference in LRP intensity in the control and 8 week treatment groups between WT and 
APP was also statistically significant (p-values<0.017 and 0.023, respectively). 
 
 
 Single factor ANOVA for all treatment groups with the WT genotype 
revealed statistically different values in the means (F=11.86, p-value<3.55e-5).  There 
was no statistical difference between the means in the APP transgenic group 
(F=0.744, p-value<0.48).  Further analysis with one-tailed t tests showed that the 
average intensities of LRP between control WT/control APP and 8 week WT/8 week 
APP are statistically different (p-values<0.017 and 0.023, respectively), though there 





































Figure 38: Average Blood Vessel Density: Average cerebral blood vessel density did 
not vary significantly across genotype or treatment group, ranging from 6-8 blood 
vessels per image field. 
 
value<0.135).  One-tailed t tests between treatment groups with the same genotype 
demonstrated that LRP was increased significantly in both the 2 week and the 8 week 
treatment WT groups (p-values<0.00023 and 0.043, respectively); there was no 
statistical difference in the increased LRP that were observed for the APP group (p-
value<0.124 and 0.139, respectively). 
Again, the average number of blood vessels was measured to determine the 
observed changes in LRP on cerebral blood vessels was due to differing levels of 
blood vessels within the images taken.   No statistical difference was found across 
different genotypes or between treatment groups by either a single factor ANOVA 
with α=0.05 or two-tailed t tests with 95% significance (for WT: F = 1.205, p-value 
<0.307; for APP: F = 2.713, p-value<0.0745).  Average values ranged from 6-8 blood 





























Figure 39: Average Intensity of LRP on Neurons: Although LRP was increased on 
neurons in all groups, this difference was only statistically significant on the control 
WT/2 week WT and control APP/8 week APP groups (p-values<0.004 and 0.033, 
respectively).   
to differences in the number of blood vessels per image.  The data also suggest that 
the blood vessel density does not change significantly with simvastatin treatment. 
The average intensity of LRP was also measured on neurons.  Bar graphs 
showed that the average intensity of LRP on neurons increased during treatment with 
simvastatin for both WT and APP groups.  This difference was statistically significant 
in the WT groups (single factor ANOVA, F = 3.997, p-value<0.023, α=0.05), but 
insignificant in the APP group (F=2.074, p-value<0.134, α=0.05).  One-tailed t tests 
showed that the difference between control WT and 2 week WT was statistically 
significant (p-value<0.004), as well as the difference between control APP and 8 
week APP (p-value<0.033).  There was no statistical difference between control WT 
and 8 week WT or control APP and 2 week APP. 











































  Overall, the levels of LRP increased on both cerebral blood vessels and on 
neurons in all treatment groups, however this increase was only statistically 
significant in 2 week WT (blood vessels and neurons), 8 week WT (blood vessels) 
and 8 week APP (neurons).  This corresponds with the data that shows that brain 
cholesterol levels were significantly decreased in the 2 and 8 week WT mice, while 
brain cholesterol was lowest in the 8 week treatment APP mice (of all other APP 
mice), suggesting that decreased brain cholesterol is associated with an increase in 
LRP on cerebral blood vessels (an inverse relationship).  This was somewhat 
unexpected since both LRP and brain cholesterol have been shown to be decreased in 
AD patients, and decreased LRP has been associated with increased levels of APP 
and ApoE.  Also, since LRP expression levels are usually directly related to IL-1 
(inflammation) and cholesterol levels, a decrease in LRP would have been the 
expected result.  One explanation for this result is that simvastatin treatment helps to 
increase LRP expression by a method not previously described.   
It is interesting to note that if the ratio of LRP on blood vessels to LRP on 
neurons is plotted, it follows a symmetric curve similar in shape to the curve that was 
obtained for blood vessel density in images.  These seems to imply that although the 
neuron density is not statistically different across treatment groups, there may be an 
artificial increase in the LRP levels on blood vessels due to this minor difference.  
This may help to explain the observed increase in LRP in the 2 week WT group. 
The 8 week APP group is somewhat easier to interpret.  Cholesterol levels in 
this group were on par with those of the control group, suggesting that although 




Figure 40: Ratio of LRP on blood vessels to LRP on neurons: The ratio of LRP on blood 
vessels and on neurons followed a trend very similar to that observed for the number of 
blood vessels per image.  This suggests that the increase in LRP observed in the 2 week 
groups is more related to the increased number of blood vessels than an actual increase in 
LRP.  This data represents the ratio of the averages, thus no standard error bars are 
included. 
significantly), astrocytes still appeared in an activated state (associated with an 
increase in inflammation).  Since increased inflammation and levels of IL-1 are 
associated with increased LRP expression, it is reasonable to conclude that increased 
inflammation in the 8 week APP group led to this increase in LRP, though further 




 Data from the experiments to test the effects of short and long-term 
simvastatin treatment on WT and APP mice has been presented.  Simvastatin 
treatment led to statistically significant decreases in brain cholesterol in WT mice 
























simvastatin showed a decreasing trend in brain cholesterol levels, though the trend 
was not statistically significant.  Plasma cholesterol levels increased during both the 
control treatment and the simvastatin treatment.  This was believed to be due to an 
effect of the high fat content of the peanut butter causing an increase in plasma 
cholesterol, as opposed to differences in the ages of the mice (verified via correlation 
analysis).  Two week treatment with simvastatin decreased the difference between 
pre- and post-treatment plasma cholesterol concentrations, and was significant in the 
2 week APP group, suggesting that 2 week treatment with simvastatin was able to 
decrease both brain and plasma cholesterol in these groups.  The 8 week treatment 
group for both WT and APP transgenic mice showed no difference when compared to 
the respective control groups.  This could possibly be due to a rebounding effect that 
has been observed in animals and humans exposed to statins: after an initial treatment 
period where the cholesterol levels are significantly reduced, the liver adapts, leading 
cholesterol levels to initially overshoot before returning to baseline [50].  Also, as 
stated before, the cholesterol levels in the brain and plasma for the 8 week treatment 
group may have been slightly inaccurate due to changing the dosage method from 
peanut butter to baby food temporarily.  Definitively, though, plasma cholesterol 
levels in the 2 week treatment groups for both WT and APP were decreased 
significantly, while brain cholesterol levels were significantly decreased in 2 week 
WT (only a trend exists in 2 week APP). 
 Immunohistochemistry analysis showed several interesting alterations in 
protein expression.  The Aβ plaque density increased significantly in all groups 




the age of the mouse.  Since only the 2 week treatment groups showed significant 
decreases in brain and plasma cholesterol, these results suggest that decreased 
cholesterol levels correlate with increased Aβ levels.  The results of the 8 week group 
are harder to discuss since there was no statistically significant decrease in brain 
cholesterol observed in these groups. It is thus suggested that decreased cholesterol 
levels provided by simvastatin treatment leads to an increase of beta amyloid levels, 
though further experiments are still needed to definitively make this statement.  
ApoE levels increased in the 2 week treated groups in both APP and WT mice 
(only WT mice were statistically significant though), while mice on 8 week treatment 
had a decrease in ApoE levels.  This would correspond with the expected result that 
as cholesterol levels decreased, ApoE would increase.  The 8 week group can be 
explained by the fact that cholesterol levels were not statistically decreased and 
astrocytes appeared to be activated in images when compared to control or 2 week 
treatment images.  Inflammation is correlated directly with an increase in ApoE.  The 
results for LRP were a bit more difficult to interpret, since the increased levels of 
LRP in the 2 week group do not seem to agree with what is known in the literature 
(LRP is decreased in AD and in models where APP is increased).  The observed trend 
in the data (increased LRP at 2 weeks on both cerebral blood vessels and on neurons; 
increased in 8 weeks on neurons) is believed to be explained by the fact that there is a 
similar trend in the number of blood vessels per image in these groups, which, 
although is not enough to be statistically different, may be artificially increasing the 
LRP levels.  Alternatively, simvastatin treatment for 2 weeks may increase LRP 




 Western blotting data for nearly all groups were not statistically 
significant.  Beta amyloid, ApoE and GFAP data showed no clear trends, while APP 
showed a decreasing trend across the APP group and LRP showed and increasing 
trend across the WT (but not APP) group.  In both WT and APP mice, synaptophysin 
showed a trend of decreasing expression with simvastatin treatment.  PSD95 levels 
also showed a decreasing trend amongst APP transgenics, though no trend was 
observed in the WT group.  This decreased expression levels of Sy38 and PSD95 in 
the APP group suggests that as brain cholesterol levels decrease, the levels of proteins 
associated with synapses also decreases.  This follows logically from the fact that 
cholesterol is needed to form and maintain synapses, and the loss of cholesterol in the 
brain should hypothetically lead to a decreased number of synapses.  
Immunohistochemistry could be used to determine synaptic density in order to further 
understand this relationship.  One reason that the western blot data may have had no 
statistical significance is the loss of information from the homogenization method that 
was used since all cell types and cellular compartments are lumped together.  This 
implies that there may have been changes that were specific to neurons, astrocytes or 
other cell types, but the Western method that was used was not able to distinguish 
this.  In future experiments, a differential centrifugation method could be used to 




Chapter 6:  When experimental data meets math: final systems 
biology model incorporating data & inflammatory pathway 
 
Model Assumptions: 
 The brain can be considered a system consisting of interactions between 
several key cell types: neurons, astrocytes, microglia, and brain endothelial cells 
(ECs).  The brain parenchymal space, filled with a combination of cerebral spinal 
fluid and a predominantly proteoglycan mesh extracellular matrix network, surrounds 
all cell types, except for brain ECs, which contact the blood on one side.  At an even 
higher level, the brain can be effectively modeled as two main compartments: the 
cerebral blood vessels and the parenchymal space.  The ventricles and the areas 
outside of this described region are neglected from this model. 
 The brain has a finite volume, thus, there exists a limit, or carrying capacity or 
concentration threshold, for the number of cells, proteins, signaling molecules, lipids 
and other biomolecules that can be contained in this volume.  Above these 
concentration thresholds, regulatory systems are triggered in an effort to return the 
system back to a state of homeostasis.  Independent of these regulatory mechanisms, 
cellular damage can occur due to activation of inflammatory pathways, mechanical 
loading, activation of apoptosis or necrosis, or changes in local osmolarity.  In this 
model, the blood is considered to be a relatively infinite sink (as in previous models 




enough to transport any molecule that is transported across the BBB and out of the 
brain. 
 The key cell types in the brain and their interactions with each other can be 
represented as a directed graph with both weak and strong connection strengths.  Not 
all cell types interact with each other, and only the brain ECs have a direct connection 
with the blood for waste removal.  Within this cellular network, each cell type 
possesses its own set of metabolic, lipidomic and proteomic pathways that are 
expressed depending on what genes are currently active.  This cellular sub-network 
can be considered cell-dependent topology.  
 
 
Figure 41: Two-level hierarchal network used to model our system.  In this model, the brain 
has been modeled as a two-level hierarchal network.  The higher level consists of the cellular 
network (neurons (N), astrocytes (A), microglia (M) and brain endothelial cells (EC).  Each of 
these cell types also has a sub-cellular network that models lipid metabolism (L), protein 




 As discussed in chapter 4 briefly, the brain can be thought of as having 
different “states”, similar to the idea of a Markovian process.  In the case described 
here, the current overall state of the brain can be modeled as the convoluted sum of 
the individual pathways that are currently being expressed by that cell type.  Initially, 
this sum would be considered the healthy state, where pathways are running 
efficiently, all biomolecules are within the normal, physiological ranges, energy 
levels are kept constant and inflammatory processes are balanced.  Over time though, 
the system may become perturbed from environmental or other triggers.  If not 
properly adjusted for, the expression of certain molecules or of pathways may be 
altered such that the system is no longer in a healthy state, but has entered into one of 
many possible disease states.  These switches from health to disease states can be 
modeled as discrete logic transitions since they occur only when a critical threshold 
for a biomolecule or other constraint condition has been reached.  The entire network 
of metabolic, lipidomic and proteomic pathways can still be modeled using 
continuous-time ordinary differential equations as described in previous chapters, 
while these discrete switching conditions are used to model regulatory mechanisms 
that shift the system state.  These switches activate the expression of new pathways or 
significant changes in the expression of currently expressed pathways, such that the 
new state is represented by an alternative set of ODEs and/or rate constants.  In this 
manner, a model similar to a hybrid automaton will be described to model the system 
as it evolves over time. 
 The following figure visually describes how the brain‟s state can evolve over 




activated.  The system state is allowed to switch from healthy  disease, from 
disease state  disease state, and under some conditions, return from a disease state 
to a healthy state.  Disease states can also combine to form conditions which are even 
further from the healthy state.  The farther that a node is removed from the healthy 




Figure 42: Disease Processes as a Markovian State Space.  It is being proposed here that diseases, 
regardless of their underlying pathogenesis mechanisms, can be modeled as Markov state space.  
The highest probability is to find the system in the healthy state, which transitions to other states 
(unhealthy states) upon exposure to an environmental stimulus or other external factor.  Over time, 
these transitions can tend towards a disease state.  Depending on the disease, this may be a final, 





Time delays play a key role in the interaction graph between the cell types, as 
well as the in the modeling of the biochemical pathways in continuous-time.  Delays 
can be caused by time needed for transcription/translation, diffusion, activation of a 
specific pathway via a cascade process, or changes in mRNA expression due to such 
activation.  As can be seen in the topology of the two-level hierarchy graph, time 
scales can vary across levels of the network as well.  At the sub-cellular level, most 
reactions take place in milliseconds-minutes range; while interactions at the cellular 
level occur in the seconds to hours range.  Overall changes at the organ may take 
hours to years to occur at an observable or measurable rate. 
Trends from biological experiments & the literature: 
 From the biological experiments that were described in the previous chapter, 
several trends from the data were important in developing the final topology of the 
network.  Decreasing cholesterol levels led to an increase in beta amyloid.  This 
suggests that the proposed role of cholesterol as an inhibitor of BACE activity is 
correct and has been included as a definitive inhibitory edge in the model.  
Experimental evidence from other sources also describe a similar trend [1, 33].  
Although there is data available that states that cholesterol promotes the generation of 
beta amyloid by increasing the activity of BACE, the experiments did not take into 
account the fact that treatment with a statin not only lowers cholesterol, but also 
decreases inflammation.  Additionally, many of these experiments have been done on 
cell lines which may not give the most accurate or relevant results when compared to 
the actual body.  Decreased cholesterol also led to an increase in ApoE and LRP 




generation rates dependent on the astrocytic cholesterol concentration.  Increased 
levels of ApoE are commonly seen in AD brains [42]. 
 From the literature, it is known that increased IL-1 expression levels, as seen 
during an inflammatory response, decreases cholesterol synthesis by 25-60% [112].  
This was modeled by adding an inhibitory rate constant to the equation for modeling 
cholesterol generation by astrocytes.  IL-1 is also known to increase the expression 
levels of ApoE and LRP, while decreasing the conversion of tryptophan precursors to 
serotonin, causing a buildup of tryptophan.   Finally, IL-1 is also known to stimulate 
the production of beta amyloid, thus creating a positive feedback loop between beta 
amyloid (which stimulates production and secretion of IL-1).   
Beta amyloid synthesis was set at 5% of the products cleaved from APP, using 
a rate that has been previously described [28].  It is interesting to note that beta 
amyloid production is not increased in AD, though a 30% decrease in clearance has 
been seen [96].  The average half-life for beta amyloid is 2 hours [30].  This half-life 
includes degradation by proteases, uptake by astrocytes and microglia, and clearance 
from the brain via the LRP-1 receptor on brain endothelial cells. 
The model was derived using Michaelis-Menten rate kinetics since a major 
assumption was that metabolic reactions were at steady state.  These reactions were 
assumed to proceed much faster than the overall rate at which the system was 
changing.  The steady state value could shift, but the actual rate at which chemical 





 Given the hierarchal nature of this model, the biochemical pathways that are 
being expressed by various cell types have been minimized to those which are either 
absolutely essential for cell survival, or required for the cell‟s main function.  The 
pathways have been divided by cell type, though several pathways, such as the need 
to have functional mitochondria and fatty acid synthesis for maintaining cell 
membranes, are included in all cell types.  Additional pathways are specific to cell 
type function; proteomic pathways have been limited to include only those proteins 
that have been implicated in playing a causal role in AD. 
Networks for Each Cell Type 
Neurons: 
- Metabolic (energy, 
neurotransmitter synthesis) 
- Fatty acid synthesis 
- Proteomic (APP, LRP) 
- 24SOH 
- Trivial amount of cytokines 
Microglia: 
- Metabolic (energy) 
- Fatty acid/cholesterol synthesis 
(for self) 
- Cytokine production (IL-1, TNFα) 
- Function: phagocytose Aβ 
Astrocytes: 
- Metabolic (energy) 
- Fatty acid & cholesterol 
synthesis (for self & neurons) 
- Proteomic (ApoE, ABCA1) 
Brain ECs: 
- Metabolic (energy) 
- Fatty acid/cholesterol synthesis 
(for self) 
- Proteomic (LRP) 
- Function: transport Aβ across 
BBB 
  The following figures describe in detail the network topology that was used 
for each cell type.  Chemical species are represented as nodes, while chemical 
reactions or interactions (inhibitory or promoting) are represented by edges.  
Molecules belonging to metabolic networks have green nodes, lipid molecules are 
Table 10: Networks for Each Cell Type.  Each cell type expresses a distinct set of 





orange, proteins are blue, cytokines are red, and all other molecules are purple.  
Inhibitory interactions are represented by red edges; promoting interactions are given 


















System of Equations: 
 A system of equations was derived to describe these interactions.  Similar 
equations were derived for each of the reactions in glycolysis, with only variations in 
the rate constants used.  Glucose metabolism in all cell types was modeled as the 
conversion of glucose to acetyl coenzyme A, modeling only steps that are key nodes 
for other important end products or important regulatory steps.  In neurons glucose 
conversion and Acetyl CoA were modeled by the following equations: 
 




 Equations for glucose usage and AcetylCoA were similar in other cell types; 
the only difference was the rate constants.  Beta amyloid was modeled as a pseudo-
one-step cleavage product of APP.  Neuronal cholesterol levels inhibited this 
generation and were modeled by adding an inhibition term to the Michaelis-Menten 
rate constant.  Beta amyloid could be degraded enzymatically, by astrocyte and 
microglia uptake or by clearance via LRP-1 on brain endothelial cells: 
 
LRP was modeled as a simply generation rate minus a degradation rate, with 
an added generation term (h) that described increased LRP production upon exposure 
to IL-1: 
 
 In astrocytes, cholesterol metabolism was modeled using simplified equations 
that studied the conversion of AcetylCoAHmgCoAmevalonatecholesterol, 






Derivation of rate constants: 
 Rate constants for the metabolic network were derived by applying a modified 
version of Kirchoff‟s current law to each node in the energy production pathways.  
This assured that material constraints were being met (conservation of mass).  Other 
rates constants were derived as percentage changes as found in the literature, or 
estimated from what data was available in the literature or through experiment. 
Nodal Analysis: 
 Nodal analysis is a useful method in identifying possible key nodes in a 
network.  The degree of every node within the sub-cellular level of the hybrid 
network described here was determined.  Nodes were divided between in nodes and 
out nodes since the graph is directed.  No difference in the degree was noted 
regardless of whether the edge was inhibitory, the step in a chemical reaction, or a 
promoting factor.  Nodes that served roles for transporting other molecules were 
assigned 1 for node in and 1 for node out.  The following table describes both the 
degree in and degree out for every node. 
Network/Chemical 
Species 
Degree In Degree Out 
(Neuron)   
Glucose 1 1 
Glycolysis 1 4 
Pyruvate 1 1 
AcetylCoA 2 3 
TCA 1 0 
Malonyl CoA 1 0 
Serotonin 2 0 
Dopamine 1 0 
Phosphatidylcholine 2 0 
Choline 1 2 
Acetylcholine 2 0 
APP 1 2 
sAPP 1 0 
Aβ 3 4 
Cholesterol 1 3 




Astrocyte   
Glucose 1 1 
Pyruvate 1 1 
AcetylCoA 2 3 
TCA 1 0 
MalonylCoA 1 0 
HmgCoA 1 1 
Mevalonate 2 1 
cholesterol 2 2 
ApoE 2 1 
ABCA1 2 1 
LRP 3 1 
Microglia   
Glucose 1 1 
Pyruvate 1 1 
AcetylCoA 2 3 
TCA 1 0 
MalonylCoA 1 0 
Cholesterol 1 0 
IL-1 2 6 
Brain Endothelial Cell   
Glucose 1 1 
Pyruvate 1 1 
AcetylCoA 1 3 
MalonylCoA 1 0 
Cholesterol 1 0 
TCA 1 0 
LRP 3 1 
 
The degree distribution, which describes the fraction of nodes having degree k, was 
also determined for this network.  The most frequent degree in was one, while the 
most frequent degree out was 0/1.  This suggests that many of the molecules that are 
modeled by this network are terminal reactions in relation to the network topology.  
There are however several nodes with relatively high degree: AcetylCoA, Aβ, LRP 
and IL-1 all have degree in or out >=2, suggesting that these are key nodes in this 
network. Creating the log-log plot of the degree versus the probability of that degree 
showed a scale-free network given by a power law with an exponent ~2.  This 








0 1 2 3 4 5 6 
P(k) 0 26/41 11/41 4/41 0 0 0 
Degree 
Out (l) 
0 1 2 3 4 5 6 
P(l) 15/41 15/41 3/41 5/41 2/41 0 1/41 
 
 
Simulation Conditions:  
 Simulations were run for 14600 days (40 years), starting from initial 
conditions that were supposed to represent the values found in the brain of an average 
25 year old.  The simulations end time point would be 65 years of age.  The system of 
equations was solved numerically using ODE45 in Matlab.  The cases were 
represented with IF statements that switched the set of differential equations or rate 



























Figure 46: Degree Distribution (top) Degree distribution for the final network 
topology. (bottom) Log-log of the degree versus the degree distribution, demonstrating 




describing the temporal concentration distribution of several key molecules were 
obtained.  Results were normalized against their initial values. 
Simulation Results: 
Reference Simulation: 
 A reference simulation was run to determine the normal expression levels for 
all molecules that were being studied.  Normal values were as follows: APP- 95; Aβ-
0.132; neuronal cholesterol- 375; astrocytic cholesterol- 37; ApoE- 962; IL-1- 14; 
LRP on brain ECs- 447.  A fast convergence is observed in most simulations. 
 
 






















































































Effect of Decreased Cholesterol Transfer Rate: 
 Decreasing the rate of transfer of cholesterol from astrocytes to neurons led to 
an increase in beta amyloid levels, a significant increase in neuronal cholesterol, a 
sustained increase in astrocytic cholesterol and mild increases in APP and ApoE.  
There are also noticeable changes in the time course at lower transfer rates, leading to 
a delay. 
Effect of Decreasing Cholesterol Production: 
 Decreasing the cholesterol production rate by astrocytes led to significant 
increases in Aβ, and mild increases in ApoE, neuronal and astrocytic cholesterol.  
These results match those that were derived from the experimental section in terms of 
a similar trend in the data. 
 
 



















































































































































































































































































































































Figure 48: Effects of Decreased Cholesterol Transfer. Decreasing the rate at which 
cholesterol was transferred from astrocytes to neurons led to an increase in steady 




Figure 49: Effect of Decreased Acetyl CoA to HmgCoA Conversion: Decreasing 
the amount of acetyl CoA to HmgCoA conversion led to a significant increase in 
steady state levels of beta amyloid.  Levels of other molecules only changed slightly 






























































































































































































































































Effect of Single Pulse Inflammation: 
 Short pulses of increased IL-1 expression (modeled to represent short duration 
infections) led to sustained increases in ApoE and LRP levels.  Neuronal cholesterol 
levels were perturbed during the duration of the sickness, and included an initial 
decrease, followed by an overshoot, before returning to baseline levels.  In all 
simulations, the final level of Aβ was increased during the duration of the illness, 
before returning to a level slightly higher than baseline (~5% increase).  ApoE levels 









































































































































































Figure 50: Effect of Short-term Inflammatory response: Short duration inflammatory 
responses were modeled using step functions to temporarily increase IL-1 levels.  This led to a 
temporally-associated increase in  ApoE, neuronal cholesterol and astrocytic cholesterol.  Aβ 
levels were increased significantly during the illness period (~200%), before returning to 




Effects of Periodic Inflammation: 
 Periodic inflammation that returned to a state of no inflammation (acute 
inflammation) led to corresponding oscillatory increases in beta amyloid levels, as 
well as significant increases in ApoE and cholesterol levels during the high 
inflammatory state.  A very weak shift upwards in beta amyloid levels was observed 
over time (~4%).  Under chronic inflammation, beta amyloid levels increased 
significantly (>10x) that was sustained for the duration of inflammation.  Under these 
conditions, ApoE levels increased significantly (~40%) while LRP levels increased 







































































































































































Figure 51: Effect of Acute Periodic Inflammation. Levels of different chemical 





Effect of Decreased Available Glucose: 
 Decreasing the amount of glucose available to all cells led a significant 
increase in Aβ levels (~50%) for the most extreme case to be modeled, a significant 













































































































































































































Figure 52: Effect of Chronic Periodic Inflammation. Chronic inflammation led 
to a significant increase in beta amyloid (>10x) and ApoE (~40%).  Neuronal 
cholesterol levels were increased only mildly (<1%) 
Figure 53: Effect of Decreased 
Glucose Levels: Decreasing 
glucose levels led to an 
increase in beta amyloid and 
ApoE, with a significant 




Effect of Increased Aβ Production: 
 Increasing the production rate of beta amyloid only led to a mild increase in 



























































































































































































































































Figure 54: Effect of increased Aβ cleavage on the network. Increasing the cleavage 
rate of beta amyloid from APP led to increased levels of beta amyloid and APP.  Other 




Discussion & Conclusion: 
 In this chapter, an updated version of the systems biology model that was 
developed in chapter 4 was developed.  This model expanded to include 41 nodes and 
was compartmentalized into 4 different cell types.  The model was expanded to 
include the role of inflammation, particularly the role of IL-1.  Several different 
simulation runs were made, looking at the roles of decreased cholesterol, increased 
inflammatory state and increased beta amyloid production.   
Decreasing the production rate of cholesterol by astrocytes led to an increase 
in beta amyloid and ApoE, which was very similar to that which was seen in the 
biological experiments that studied the effect of simvastatin.  Chronic inflammation 
was found to profoundly affect the system, leading to prolonged increases in the level 
of ApoE and Aβ.  This suggests that inflammation may play a unique causal role in 
AD pathogenesis that warrants further simulation and experimentation.  Increasing 
the cleavage rate of beta amyloid had little direct effect on other molecules in the 
system over the range that was studied.  This suggests that increased cleavage does 
not have a significant effect on the network system unless other factors or triggering 
events are met.  This is not to say that increased beta amyloid levels do not play a role 
in the pathogenesis of AD, such as that seen in familial AD, but that several things 
may be at play for why increased beta amyloid levels are present and affect the 
system.  For example, significantly increased levels of any protein will negatively 
affect the state of a biological system, putting strain on resources to clear the protein, 
possibly competitive interactions between the increased protein and other proteins 




and viscosity of the extracellular fluid, all of which could have negative downstream 
effects.  Thus, the increased Aβ generation rates seen in familial AD may initially 
operate under a different pathogenesis mechanism, before converging onto a similar 
disease process that is observed in late-onset AD.  The model developed here further 
suggests that unless beta amyloid levels pass a threshold level and initiate an 
inflammatory response that beta amyloid alone may not be able to initiate the 
pathologic profile seen in AD.   
It should be noted that the simulation results converged quite quickly since the 
equation used were written to model the steady state approximations and simply study 
the changes in steady states observed after different perturbations.  This model is the 
first network model for AD for looking not just at cellular interactions, but also at the 
metabolic, proteomic and lipidomic networks that underlie these cellular interactions, 
and represents a significant advance forward in using mathematical modeling to 






















Chapter 7:  Conclusions & Future Work 
 
Conclusions: 
 As stated back in Chapter 2, there are an array of risk factors for AD, many of 
which inflammation plays a significant role in pathology.  It is well-accepted in the 
medical field that metabolic syndrome, another disease caused by general 
inflammation in the body, that it is not a single or small number of risk factors that 
lead to initiation of the disease process.  The same idea has been proposed for cancer 
and diabetes.  In the same manner of thinking, it is reasonable to propose that having 
only 1or 2 risk factors for AD (excluding those factors which are purely genetic) does 
not guarantee that AD will occur in the future.  It is only when several or more risk 
factors are present that disease occurs, that is, that there is a relative „catastrophe‟ in 
the biological system which disrupts multiple interdependent biochemical networks.  
This concept would help to explain some of the variability seen between studies 
(aside from the variability due to biased or poorly designed experiments).  It also 
would help to bring together many studies that would otherwise seem unrelated or 
contradictory, and give the results of epidemiological studies a better understanding. 
 In addition to this, importance should be placed on how AD pathology relates 
to disease causation and symptomology.  For example, although Aβ levels are 
increased in the brains of nearly all individuals affected by AD, leading to the 
traditional belief that these plaques or oligomers are the cause of disease, this 
perspective fails to take into account the possibility that Aβ buildup may just be a 




Just like increased white cell count is not the cause of an infection, but nearly the 
response to an infection, Aβ may also have a similar role in AD pathogenesis.   
Along this same perspective, disease states in general can be viewed as the 
response of a system to different inputs.  Preceding a disease, many different inputs 
may be received by the body.  These inputs must be „decrypted‟, processed, 
interpreted correctly and a decision must be made as to how to keep the organism in a 
state of homeostasis.  A simple survey of regulatory and signal transduction pathways 
clearly demonstrates that differing inputs often have convergent outputs and 
moreover these pathways may converge even before a response is taken.  For 
example, intracellular levels of calcium change in response to neurotransmitter 
binding, ligand binding, and in response to the IP3/DAG pathway.  This similarity in 
network topology, and mutual sharing of common chemical nodes with high traffic, is 
an evolutionarily advantageous method that living organisms have capitalized on to 
prevent the need of extra molecules necessary for functioning and putting an upper 
bound on the amount of genetic material that an organism would need to survive.  
This does, however, have drawbacks when a mutation occurs in one of these 
pathways, or if the regulation of a pathway is in disarray.  In such a case, the 
robustness of the system is lost and a disease state is necessitated if balance is not 
maintained within the system. 
 Inflammation is perhaps the single most important state that has to be 
balanced in the human body.  Mild to moderate levels of inflammation over short 
periods of time may actually be beneficial to the body as a system, stimulating the 




of new, healthy cells.  In AD and many other disease states, this balance is off, 
leading to cell death and disease.  The importance of the inflammatory pathway was 
demonstrated by the results of the final model, which showed that for even a short 
duration increase of the pro-inflammatory molecule, IL-1, there are significant and 
long-term changes the expression patterns of ApoE and LRP-1, in addition to short-
term alterations in cholesterol metabolism.  It is interesting to note that changes to 
cholesterol levels were relatively more transient than those to protein expression 
levels, though it provides nice insight into the possible disease process. 
 From the experimental results, cholesterol metabolism does seem to play a 
contributory, if not significant role, in the progression of AD.  This role, which may 
be prominent due to the high interconnectivity of the cholesterol pathway with other 
key metabolic pathways, has effects on several other pathways that may not directly 
be connected to cholesterol or its metabolites.  
Future Work 
 Modeling AD and the multitude of pathways and interactions related 
or possibly related to the disease process is an enormous task.  The work presented 
here just starts to touch the tip of what is possible in terms of using mathematical 
modeling to better understand disease processes, particularly AD.  There are many 
avenues of open research in this area.  Of particular interest to myself would be to 
look at the role of genetics and epigenetics in AD pathogenesis, as well as the role 
that chronic stress and adrenal hormones may play in the disease process, in 
combination with continued biological experiments.  Additionally, it would be 




psychological, and endocrinological aspects of AD in hopes of creating a unified 
model for AD pathogenesis that looks at the disease from the various aspects.  Future 
experiments with human subjects would help to gather more relevant data for the 
model, needed rate constants and further information about the topology of the 
interacting networks.  Expanding this model to include stochastic rate constants, and 
additional genomic and proteomic interactions would help to make an even more 
accurate mathematical description for AD pathogenesis that, when combined with 
biological data and interpreted in the light of such data, could help to create new 
















Figure 2: ~50% increased levels of beta amyloid when no feedback control by cholesterol.  
When feedback by Aβ is removed, normal levels of cholesterol and Aβ observed. 
Role of Feedback Inhibition
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